1
|
Bauermeister JA, Horvath KJ, Lin WY, Golinkoff JM, Claude KF, Dowshen N, Castillo M, Sullivan PS, Paul M, Hightow-Weidman L, Stephenson R. Enhancing routine HIV and STI testing among young men who have sex with men: primary outcomes of the get connected clinical randomized trial (ATN 139). BMC Public Health 2024; 24:1072. [PMID: 38632603 PMCID: PMC11025185 DOI: 10.1186/s12889-024-18522-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2024] [Accepted: 04/04/2024] [Indexed: 04/19/2024] Open
Abstract
BACKGROUND Regular HIV and STI testing remain a cornerstone of comprehensive sexual health care. In this study, we examine the efficacy of Get Connected, a WebApp that combines test locators with personalized educational resources, in motivating young men who have sex with men (YMSM) to undergo regular HIV and STI testing. METHODS Participants were randomly placed in one of two conditions. The first condition included the full version of GC (GC-PLUS), which included content tailored to users' psychosocial characteristics (e.g., age, race/ethnicity, relationship status, HIV/STI testing history). The second condition served as our attention-control and only included the testing locator (GC-TLO) for HIV/STI testing services. Participants were recruited from three cities (Houston, Philadelphia, and Atlanta) characterized by high HIV incidence. Assessments were collected at 1, 3-, 6-, 9- and 12-month follow-ups. RESULTS Both versions of GC were acceptable and efficacious in increasing routine HIV and STI testing over a 12-month period. 40% of the sample reported testing at least twice, with no main effects observed across the two intervention arms (OR = 1.11; 95% CI: 0.69, 1.80), p =.66). Greater intervention effects were observed among YMSM who engaged more frequently with the intervention, with regional differences observed. CONCLUSIONS Our findings underscore the need to cater to the diverse needs of YMSM through multilevel approaches. Broadly, mHealth HIV/STI testing interventions, such as Get Connected, would benefit from matching technologies to the local context to have the greatest impact. TRIAL REGISTRATION This study is registered on ClinicalTrials.gov (NCT03132415).
Collapse
Affiliation(s)
- J A Bauermeister
- University of Pennsylvania, 418 Curie Blvd, Room 222L, 19104, Philadelphia, PA, USA.
| | - K J Horvath
- San Diego State University, San Diego, CA, USA
| | - W Y Lin
- University of Pennsylvania, 418 Curie Blvd, Room 222L, 19104, Philadelphia, PA, USA
| | - J M Golinkoff
- University of Pennsylvania, 418 Curie Blvd, Room 222L, 19104, Philadelphia, PA, USA
| | - K F Claude
- Florida State University, Tallahassee, FL, USA
| | - N Dowshen
- University of Pennsylvania, 418 Curie Blvd, Room 222L, 19104, Philadelphia, PA, USA
- Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - M Castillo
- Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | | | - M Paul
- Baylor College of Medicine, Houston, TX, USA
| | | | | |
Collapse
|
2
|
Glass B, Bergman D, Parro V, Kobayashi L, Stoker C, Quinn R, Davila A, Willis P, Brinckerhoff W, Warren-Rhodes K, Wilhelm M, Caceres L, DiRuggiero J, Zacny K, Moreno-Paz M, Dave A, Seitz S, Grubisic A, Castillo M, Bonaccorsi R. The Atacama Rover Astrobiology Drilling Studies (ARADS) Project. Astrobiology 2023; 23:1245-1258. [PMID: 38054949 PMCID: PMC10750311 DOI: 10.1089/ast.2022.0126] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 09/01/2023] [Indexed: 12/07/2023]
Abstract
With advances in commercial space launch capabilities and reduced costs to orbit, humans may arrive on Mars within a decade. Both to preserve any signs of past (and extant) martian life and to protect the health of human crews (and Earth's biosphere), it will be necessary to assess the risk of cross-contamination on the surface, in blown dust, and into the near-subsurface (where exploration and resource-harvesting can be reasonably anticipated). Thus, evaluating for the presence of life and biosignatures may become a critical-path Mars exploration precursor in the not-so-far future, circa 2030. This Special Collection of papers from the Atacama Rover Astrobiology Drilling Studies (ARADS) project describes many of the scientific, technological, and operational issues associated with searching for and identifying biosignatures in an extreme hyperarid region in Chile's Atacama Desert, a well-studied terrestrial Mars analog environment. This paper provides an overview of the ARADS project and discusses in context the five other papers in the ARADS Special Collection, as well as prior ARADS project results.
Collapse
Affiliation(s)
- B. Glass
- NASA Ames Research Center, Moffett Field, California, USA
| | - D. Bergman
- Honeybee Robotics, Pasadena, California, USA
| | - V. Parro
- Centro de Astrobiología (CAB), CSIC-INTA, Torrejon de Ardoz, Spain
| | - L. Kobayashi
- NASA Ames Research Center, Moffett Field, California, USA
| | - C. Stoker
- NASA Ames Research Center, Moffett Field, California, USA
| | - R. Quinn
- NASA Ames Research Center, Moffett Field, California, USA
| | - A. Davila
- NASA Ames Research Center, Moffett Field, California, USA
| | - P. Willis
- NASA Jet Propulsion Laboratory, Pasadena, California, USA
| | | | - K. Warren-Rhodes
- NASA Ames Research Center, Moffett Field, California, USA
- SETI Institute, Carl Sagan Center, Mountain View, California, USA
| | - M.B. Wilhelm
- NASA Ames Research Center, Moffett Field, California, USA
| | - L. Caceres
- University of Antofagasta, Antofagasta, Chile
| | | | - K. Zacny
- Honeybee Robotics, Pasadena, California, USA
| | - M. Moreno-Paz
- Centro de Astrobiología (CAB), CSIC-INTA, Torrejon de Ardoz, Spain
| | - A. Dave
- NASA Ames Research Center, Moffett Field, California, USA
| | - S. Seitz
- NASA Ames Research Center, Moffett Field, California, USA
| | - A. Grubisic
- NASA Goddard Space Flight Center, Greenbelt, Maryland, USA
| | - M. Castillo
- NASA Goddard Space Flight Center, Greenbelt, Maryland, USA
| | - R. Bonaccorsi
- NASA Ames Research Center, Moffett Field, California, USA
- SETI Institute, Carl Sagan Center, Mountain View, California, USA
| |
Collapse
|
3
|
Villacieros-Álvarez J, Espejo C, Arrambide G, Castillo M, Carbonell-Mirabent P, Rodriguez M, Bollo L, Castilló J, Comabella M, Galán I, Midaglia L, Mongay-Ochoa N, Nos C, Rio J, Rodríguez-Acevedo B, Sastre-Garriga J, Tur C, Vidal-Jordana A, Vilaseca A, Zabalza A, Auger C, Rovira A, Montalban X, Tintoré M, Cobo-Calvo Á. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis. Ann Neurol 2023. [PMID: 37705507 DOI: 10.1002/ana.26793] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 08/21/2023] [Accepted: 09/07/2023] [Indexed: 09/15/2023]
Abstract
OBJECTIVE Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) distinguish multiple sclerosis (MS) from MOG-associated disease in most cases. However, studies analyzing MOG-Ab at the time of a first demyelinating event suggestive of MS in adults are lacking. We aimed to (1) evaluate the prevalence of MOG-Ab in a first demyelinating event suggestive of MS and (2) compare clinical and paraclinical features between seropositive (MOG-Ab+) and seronegative (MOG-Ab-) patients. METHODS Six hundred thirty adult patients with available serum samples obtained within 6 months from the first event were included. MOG-Ab were analyzed using a live cell-based assay. Statistical analyses included parametric and nonparametric tests, logistic regression, and survival models. RESULTS MOG-Ab were positive in 17 of 630 (2.7%). Fourteen out of 17 (82.4%) MOG-Ab+ patients presented with optic neuritis (ON) compared to 227of 613 (37.0%) MOG-Ab- patients (p = 0.009). Cerebrospinal fluid-restricted oligoclonal bands (CSF-OBs) were found in 2 of 16 (12.5%) MOG-Ab+ versus 371 of 601 (61.7%) MOG-Ab- subjects (p < 0.001). Baseline brain magnetic resonance imaging (MRI) was normal in 9 of 17 (52.9%) MOG-Ab+ versus 153 of 585 (26.2%) MOG-Ab- patients (p = 0.029). Absence of CSF-OBs and ON at onset were independently associated with MOG-Ab positivity (odds ratio [OR] = 9.03, 95% confidence interval [CI] = 2.04-53.6, p = 0.009; and OR = 4.17, 95% CI = 1.15-19.8, p = 0.042, respectively). Of MOG-Ab+ patients, 22.9% (95% CI = 0.0-42.7) compared to 67.6% (95% CI = 63.3-71.3) of MOG-Ab- patients fulfilled McDonald 2017 criteria at 5 years (log-rank p = 0.003). INTERPRETATION MOG-Ab are infrequent in adults with a first demyelinating event suggestive of MS. However, based on our results, we suggest to determine these antibodies in those patients with ON and absence of CSF-OBs, as long as the brain MRI is not suggestive of MS. ANN NEUROL 2023.
Collapse
Affiliation(s)
- Javier Villacieros-Álvarez
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Carmen Espejo
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Georgina Arrambide
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Mireia Castillo
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Pere Carbonell-Mirabent
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Marta Rodriguez
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Luca Bollo
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Joaquín Castilló
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Manuel Comabella
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Ingrid Galán
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Luciana Midaglia
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Neus Mongay-Ochoa
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Carlos Nos
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Jordi Rio
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Breogan Rodríguez-Acevedo
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Jaume Sastre-Garriga
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Carmen Tur
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Angela Vidal-Jordana
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Andreu Vilaseca
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Ana Zabalza
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Cristina Auger
- Autonomous University of Barcelona, Barcelona, Spain
- Section of Neuroradiology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Alex Rovira
- Autonomous University of Barcelona, Barcelona, Spain
- Section of Neuroradiology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Xavier Montalban
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Mar Tintoré
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| | - Álvaro Cobo-Calvo
- Neurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain
- Autonomous University of Barcelona, Barcelona, Spain
| |
Collapse
|
4
|
Castillo M, Freire E, Romero VI. Primary ciliary dyskinesia diagnosis and management and its implications in America: a mini review. Front Pediatr 2023; 11:1091173. [PMID: 37744431 PMCID: PMC10514901 DOI: 10.3389/fped.2023.1091173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Accepted: 08/29/2023] [Indexed: 09/26/2023] Open
Abstract
Introduction Primary ciliary dyskinesia (PCD) is a rare genetic disorder that can result in significant morbidity and mortality if left untreated. Clinical manifestations of PCD include recurrent respiratory infections, laterality defects, and infertility, all of which arise from impaired or absent ciliary motility. Diagnostic approaches for PCD may include high-speed video microscopy, measurement of nasal nitric oxide levels, and genetic testing; however, no single definitive diagnostic test exists. The present study aims to highlight the lack of standardized diagnostic and treatment guidelines for PCD in Latin America (Central and South America, and the Caribbean). To this effect, we compared North American and European recommendations for the diagnosis and management of PCD and found that certain diagnostic tools and treatment options mentioned in these guidelines are not readily accessible in many Latin American countries. Methods & Results This review gathers disease information in North America, Europe, and Latin America organizing guideline results into tables for clarity and potential interventions. Management information for Latin America is inferred from case reports, as most findings are from North American recommendations and studies on PubMed, Google Scholar, and Scopus. Treatment and management information is based on North American and European standards.Among 5,774 publications reviewed, only 15 articles met the inclusion criteria (focused on PCD management, peer-reviewed, and located in America). No clinical guideline for PCD in Latin America was found, but recommendations on respiratory management from Colombia and Chile were discovered. The lack of guidelines in Latin America may originate from limited resources and research on the disease in those countries. Discussion PCD lacks documentation, research, and recommendations regarding its prevalence in Latin America, likely due to unfavorable economic conditions. This disadvantage results in limited access to diagnostic tests available in North America and Europe. The PICADAR score, discussed in this review, can be used in low-income nations as a screening tool for the disorder.
Collapse
Affiliation(s)
| | | | - V. I. Romero
- School of Medicine, Universidad San Francisco de Quito, Quito, Ecuador
| |
Collapse
|
5
|
Kanchi R, Chacon L, D'Silva E, Salan-Gomez M, Leon-Pena A, Castillo M, Gunaratne P, Mendez CH, Coarfa C, Loor G. Donorexosomebiomarkers for Primary Graft Dysfunction in Transplants Using Ex-Vivo Lung Perfusion. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
6
|
Harris E, Sewanan L, Topkara V, Fried J, Raikhelkar J, Colombo P, Yuzefpolskaya M, DeFilippis E, Latif F, Castillo M, Lam E, Takeda K, Chernovolenko M, Einstein A, Johnson L, Uriel N, Sayer G, Clerkin K. Isolated Microvascular Cardiac Allograft Vasculopathy is Associated with an Increased Risk of Death or Retransplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
7
|
Ramírez-Bayard IE, Mejía F, Medina-Sánchez JR, Cornejo-Reyes H, Castillo M, Querol-Audi J, Martínez-Torres AO. Prevalence of Plasmid-Associated Tetracycline Resistance Genes in Multidrug-Resistant Escherichia coli Strains Isolated from Environmental, Animal and Human Samples in Panama. Antibiotics (Basel) 2023; 12:280. [PMID: 36830191 PMCID: PMC9952377 DOI: 10.3390/antibiotics12020280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 01/20/2023] [Accepted: 01/21/2023] [Indexed: 02/04/2023] Open
Abstract
Antimicrobial resistance bacteria are nowadays ubiquitous. Its presence has been reported in almost every type of source, from water for agricultural and recreative use, water distribution pipes, and wastewater, to food, fomites, and clinical samples. Enterobacteriaceae, especially Escherichia coli, are not the exception, showing an increased resistance to several antibiotics, causing a global health and economic burden. Therefore, the monitoring of fecal microbiota is important because it is present in numerous reservoirs where gene transfer between commensal and virulent bacteria can take place, representing a potential source of resistant E. coli. In this work, antibiotic resistance profiles of 150 E. coli isolates from environmental, animal, and human samples, collected in three rural areas in Panama, were analyzed. A total of 116 isolates were resistant to at least one of the nine antibiotics tested. Remarkably, almost 100% of these exhibited resistance to tetracycline. Plasmid-associated tetA and tetB genes were detected in 42.86% of the isolates analyzed, tetA being the most prevalent. These results suggest that tetracycline resistance would be used as a convenient indicator of genetic horizontal transfer within a community.
Collapse
Affiliation(s)
- I. E. Ramírez-Bayard
- Experimental and Applied Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Water Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Master in Environmental Microbiology, Faculty of Natural and Exact Sciences and Technology, Universidad de Panamá, Panama City 0820, Panama
| | - F. Mejía
- Experimental and Applied Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Water Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Master in Environmental Microbiology, Faculty of Natural and Exact Sciences and Technology, Universidad de Panamá, Panama City 0820, Panama
| | - J. R. Medina-Sánchez
- Experimental and Applied Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Water Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Master in Environmental Microbiology, Faculty of Natural and Exact Sciences and Technology, Universidad de Panamá, Panama City 0820, Panama
| | - H. Cornejo-Reyes
- Experimental and Applied Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Water Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Master in Environmental Microbiology, Faculty of Natural and Exact Sciences and Technology, Universidad de Panamá, Panama City 0820, Panama
| | | | - J. Querol-Audi
- Experimental and Applied Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Water Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Master in Environmental Microbiology, Faculty of Natural and Exact Sciences and Technology, Universidad de Panamá, Panama City 0820, Panama
- Sistema Nacional de Investigación (SNI), SENACYT, Panama City 0816, Panama
| | - A. O. Martínez-Torres
- Experimental and Applied Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Water Microbiology Laboratory, Vice Rectory of Research and Postgraduate Affairs, Universidad de Panamá, Panama City 0820, Panama
- Master in Environmental Microbiology, Faculty of Natural and Exact Sciences and Technology, Universidad de Panamá, Panama City 0820, Panama
- Sistema Nacional de Investigación (SNI), SENACYT, Panama City 0816, Panama
| |
Collapse
|
8
|
Vega E, Arrambide G, Olivé G, Castillo M, Felipe-Rucián A, Tintoré M, Montalban X, Espejo C, Sepúlveda M, Armangué T, Cobo-Calvo A. Non-ADEM encephalitis in patients with myelin oligodendrocyte glycoprotein antibodies: a systematic review. Eur J Neurol 2023; 30:1515-1527. [PMID: 36704861 DOI: 10.1111/ene.15684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Revised: 11/21/2022] [Accepted: 12/22/2022] [Indexed: 01/28/2023]
Abstract
BACKGROUND AND PURPOSE Non-(acute disseminated encephalomyelitis) (non-ADEM) encephalitis and/or fluid attenuated inversion recovery hyperintense lesions in anti-myelin-oligodendrocyte-glycoprotein-associated encephalitis with seizures (FLAMES) are rarely described in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies (Abs). The aim was (i) to describe the clinical features and disease course of children and adults with non-ADEM encephalitis and/or FLAMES associated with MOG Abs and (ii) to describe their association with other central nervous system autoantibodies. METHODS This was a systematic review following the PRISMA guidelines. Patients fulfilled criteria for non-ADEM encephalitis and/or FLAMES, and all were MOG Ab positive. RESULTS In total, 83 (79%) patients with non-ADEM encephalitis (48 also had FLAMES) and 22 (21%) with isolated FLAMES were included. At the first episode, children (n = 45) had more infections (11/45, 24.4%; p = 0.017) and more of the phenotype consisting of non-ADEM encephalitis (42/45, 93.3%; p = 0.014) than adults (n = 38). Children had more episodes consistent with working memory deficits (25/54, 46.3%; p = 0.014) but fewer psychiatric symptoms (16/54, 29.6%; p = 0.002). Twenty-eight (40.6%) of 69 patients had N-methyl-d-aspartate receptor (NMDAR) Abs in cerebrospinal fluid (CSF), being more frequent in adults (19/29, 65.5%; p < 0.001). Compared to negatives, positive CSF NMDAR Abs had more relapses (14/20, 70%; p = 0.050), required ventilatory support more frequently (8/34, 23.5%; p = 0.009) and had more psychiatric episodes (28/34, 82%; p < 0.001) or abnormal movements (14/34, 41.2%; p = 0.008). Apart from an older age in FLAMES, positive and negative CSF NMDAR Ab groups shared similar features. CONCLUSION Non-ADEM encephalitis patients with MOG Abs show specific clinical and radiological features, depending on the age at first episode. The presence of MOG Abs in non-ADEM encephalitis patients should not rule out to test other autoantibodies, especially concomitant NMDAR Abs in patients with suggestive symptoms such as behavioural or movement alterations.
Collapse
Affiliation(s)
- Enrique Vega
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
| | - Georgina Arrambide
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
| | - Gemma Olivé
- Pediatric Neuroimmunology Unit, Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona, Barcelona, Spain
| | - Mireia Castillo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
| | - Ana Felipe-Rucián
- Department of Pediatric Neurology, Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Mar Tintoré
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
| | - Xavier Montalban
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
| | - Carmen Espejo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
| | - María Sepúlveda
- Neuroimmunology Program, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Thais Armangué
- Pediatric Neuroimmunology Unit, Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona, Barcelona, Spain.,Neuroimmunology Program, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Alvaro Cobo-Calvo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
| |
Collapse
|
9
|
Arrambide G, Espejo C, Carbonell-Mirabent P, Dieli-Crimi R, Rodríguez-Barranco M, Castillo M, Auger C, Cárdenas-Robledo S, Castilló J, Cobo-Calvo Á, Galán I, Midaglia L, Nos C, Otero-Romero S, Río J, Rodríguez-Acevedo B, Ruiz-Ortiz M, Salerno A, Tagliani P, Tur C, Vidal-Jordana A, Zabalza A, Sastre-Garriga J, Rovira A, Comabella M, Hernández-González M, Montalban X, Tintore M. The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. Brain 2022; 145:3931-3942. [PMID: 35727945 DOI: 10.1093/brain/awac220] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 05/10/2022] [Accepted: 05/29/2022] [Indexed: 11/13/2022] Open
Abstract
Intrathecal production of kappa free light chains (KFLC) occurs in multiple sclerosis and can be measured using the KFLC index. KFLC index values can be determined more easily than oligoclonal bands (OB) detection and seem more sensitive than the immunoglobulin (Ig)G index to diagnose multiple sclerosis. We assessed the value of OB, KFLC index cut-offs 5.9, 6.6, and 10.61, and IgG index to diagnose multiple sclerosis with prospectively acquired data from a clinically isolated syndrome (CIS) inception cohort. We selected patients with sufficient data to determine OB positivity, MRI dissemination in space (DIS) and time (DIT), IgG index, and sufficient quantities of paired CSF and blood samples to determine KFLC indexes (n = 214). We used Kendall´s Tau coefficient to estimate concordance; calculated the number of additional diagnoses when adding each positive index to DIS and positive OB; performed survival analyses for OB and each index with the outcomes second attack and 2017 MRI DIS and DIT; and estimated the diagnostic properties of OB and the different indexes for the abovementioned outcomes at five years. OB were positive in 138 patients (64.5%), KFLC-5.9 in 136 (63.6%), KFLC-6.6 in 135 (63.1%), KFLC-10.61 in 126 (58.9%) and IgG index in 101 (47.2%). The highest concordance was between OB and KFLC-6.6 (τ=0.727) followed by OB and KFLC-5.9 (τ=0.716). Combining DIS plus OB or KFLC-5.9 increased the number of diagnosed patients by 11 (5.1%), with KFLC-6.6 by 10 (4.7%), with KFLC-10.61 by 9 (4.2%), and with IgG index by 3 (1.4%). Patients with positive OB or indexes reached second attack and MRI DIS and DIT faster than patients with negative results (P < 0.0001 except IgG index in second attack: P = 0.016). In multivariable Cox models [aHR (95% CI)], the risk for second attack was very similar between KFLC-5.9 [2.0 (0.9-4.3), P = 0.068] and KFLC-6.6 [2.1 (1.1-4.2), P = 0.035]. The highest risk for MRI DIS and DIT was demonstrated with KFLC-5.9 [4.9 (2.5-9.6), P < 0.0001], followed by KFLC-6.6 [3.4 (1.9-6.3), P < 0.0001]. KFLC-5.9 and KFLC-6.6 had a slightly higher diagnostic accuracy than OB for second attack (70.5, 71.1, and 67.8) and MRI DIS and DIT (85.7, 85.1, and 81.0). KFLC indexes 5.9 and 6.6 performed slightly better than OB to assess multiple sclerosis risk and in terms of diagnostic accuracy. Given the concordance between OB and these indexes, we suggest using DIS plus positive OB or positive KFLC index as a modified criterion to diagnose multiple sclerosis.
Collapse
Affiliation(s)
- Georgina Arrambide
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Carmen Espejo
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Pere Carbonell-Mirabent
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Romina Dieli-Crimi
- Immunology Department, Vall d'Hebron Hospital Universitari. 08035 Barcelona, Spain
| | - Marta Rodríguez-Barranco
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Mireia Castillo
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Cristina Auger
- Section of Neuroradiology and Magnetic Resonance Unit. Department of Radiology (IDI). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Simón Cárdenas-Robledo
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain.,Department of Neurology, Multiple Sclerosis Center (CEMHUN), Hospital Universitario Nacional de Colombia. 111321 Bogotá, Colombia
| | - Joaquín Castilló
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Álvaro Cobo-Calvo
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Ingrid Galán
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Luciana Midaglia
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Carlos Nos
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Susana Otero-Romero
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Jordi Río
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Breogán Rodríguez-Acevedo
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Mariano Ruiz-Ortiz
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain.,Department of Neurology, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain
| | - Annalaura Salerno
- Section of Neuroradiology and Magnetic Resonance Unit. Department of Radiology (IDI). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Paula Tagliani
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Carmen Tur
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Angela Vidal-Jordana
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Ana Zabalza
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Jaume Sastre-Garriga
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Alex Rovira
- Section of Neuroradiology and Magnetic Resonance Unit. Department of Radiology (IDI). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Manuel Comabella
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Manuel Hernández-González
- Immunology Department, Vall d'Hebron Hospital Universitari. 08035 Barcelona, Spain.,Diagnostic Immunology Research Group, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Xavier Montalban
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| | - Mar Tintore
- Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona. 08035 Barcelona, Spain
| |
Collapse
|
10
|
Abdulghani S, Afonso Â, Castillo M, Martín-Fernández J, Franco I, Parreira B, Couto A, Bruges-Armas J, Rodrigues AM, Gonçalves A, Dias A, Toader I, Lopes A, Faria C, Marques F, Sousa JC, Silvestre R, Pereira P, Correia M, Maia L, Canhão H, Dias S. The Role of Biobanks in the Fight against COVID-19 Pandemic: The Portuguese Response. ACTA MEDICA PORT 2022; 35:411-415. [PMID: 35522822 DOI: 10.20344/amp.17856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 04/08/2022] [Accepted: 04/12/2022] [Indexed: 11/20/2022]
Affiliation(s)
- Saba Abdulghani
- CHAIN Biobank. Comprehensive Health Research Center (CHRC). Lisbon; Chronic Diseases Research Centre (CEDOC). NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Portugal
| | - Ângela Afonso
- Biobanco-IMM. Instituto de Medicina Molecular. Faculdade de Medicina. Universidade de Lisboa. Lisbon. Portugal
| | - Mireia Castillo
- Champalimaud Foundation Biobank. Champalimaud Centre for the Unknown. Fundação Champalimaud. Lisbon. Portugal
| | - Javier Martín-Fernández
- Champalimaud Foundation Biobank. Champalimaud Centre for the Unknown. Fundação Champalimaud. Lisbon. Portugal
| | - Inês Franco
- Champalimaud Foundation Biobank. Champalimaud Centre for the Unknown. Fundação Champalimaud. Lisbon. Portugal
| | - Bruna Parreira
- Comprehensive Health Research Center (CHRC). NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Serviço Especializado de Epidemiologia e Biologia Molecular (SEEBMO). Hospital de Santo Espírito da Ilha Terceira (HSEIT). Azores. Portugal
| | - Ana Couto
- Comprehensive Health Research Center (CHRC). NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Serviço Especializado de Epidemiologia e Biologia Molecular (SEEBMO). Hospital de Santo Espírito da Ilha Terceira (HSEIT). Azores. Portugal
| | - Jácome Bruges-Armas
- Comprehensive Health Research Center (CHRC). NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Serviço Especializado de Epidemiologia e Biologia Molecular (SEEBMO). Hospital de Santo Espírito da Ilha Terceira (HSEIT). Azores. Portugal
| | - Ana Maria Rodrigues
- CHAIN Biobank. Comprehensive Health Research Center (CHRC). Lisbon. Chronic Diseases Research Centre (CEDOC). NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Portugal
| | - Ana Gonçalves
- i3S - Instituto de Investigação e Inovação em Saúde. University of Porto. Porto. Institute of Molecular Pathology and Immunology (Ipatimup). University of Porto. Porto. Portugal
| | - Alexandre Dias
- i3S - Instituto de Investigação e Inovação em Saúde. University of Porto. Porto. Institute of Molecular Pathology and Immunology (Ipatimup). University of Porto. Porto. Portugal
| | - Ionela Toader
- Biobanco-IMM. Instituto de Medicina Molecular. Faculdade de Medicina. Universidade de Lisboa. Lisbon. Portugal
| | - Andreia Lopes
- Biobanco-IMM. Instituto de Medicina Molecular. Faculdade de Medicina. Universidade de Lisboa. Lisbon. Portugal
| | - Cláudia Faria
- Biobanco-IMM. Instituto de Medicina Molecular. Faculdade de Medicina. Universidade de Lisboa. Lisbon. Portugal
| | - Fernanda Marques
- Life and Health Sciences Research Institute (ICVS). School of Medicine. University of Minho. Braga. ICVS/3B's - PT Government Associate Laboratory. Braga. Portugal
| | - João Carlos Sousa
- Life and Health Sciences Research Institute (ICVS). School of Medicine. University of Minho. Braga. ICVS/3B's - PT Government Associate Laboratory. Braga. Portugal
| | - Ricardo Silvestre
- Life and Health Sciences Research Institute (ICVS). School of Medicine. University of Minho. Braga. ICVS/3B's - PT Government Associate Laboratory. Braga. Portugal
| | - Paulo Pereira
- Chronic Diseases Research Centre (CEDOC). NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Portugal
| | - Manuel Correia
- Department of Neurology. Centro Hospitalar Universitário do Porto. Porto. Instituto de Ciências Biomédicas Abel Salazar. University of Porto. Porto. Portugal
| | - Luís Maia
- i3S - Instituto de Investigação e Inovação em Saúde. University of Porto. Porto. Department of Neurology. Centro Hospitalar Universitário do Porto. Porto. Instituto de Ciências Biomédicas Abel Salazar. University of Porto. Porto. Portugal
| | - Helena Canhão
- CHAIN Biobank. Comprehensive Health Research Center (CHRC). Lisbon. Chronic Diseases Research Centre (CEDOC). NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Portugal
| | - Sérgio Dias
- Biobanco-IMM. Instituto de Medicina Molecular. Faculdade de Medicina. Universidade de Lisboa. Lisbon. Portugal
| |
Collapse
|
11
|
Zabalza A, Arrambide G, Otero-Romero S, Pappolla A, Tagliani P, López-Maza S, Cárdenas-Robledo S, Esperalba J, Fernández-Naval C, Martínez-Gallo M, Castillo M, Bonastre M, Resina-Salles M, Bertran J, Rodriguez-Barranco M, Carbonell-Mirabent P, Gonzalez M, Merchan M, Quiroga-Varela A, Miguela A, Gómez I, Álvarez G, Robles R, Perez Del Campo D, Queralt X, Soler MJ, Agraz I, Martinez-Valle F, Rodríguez-Acevedo B, Midaglia L, Vidal-Jordana Á, Cobo-Calvo Á, Tur C, Galan I, Castillo J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Ramió-Torrentà L, Tintoré M, Montalban X. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases? Mult Scler 2022; 28:1138-1145. [PMID: 35475363 DOI: 10.1177/13524585221089540] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear. OBJECTIVES We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID). METHODS Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers. RESULTS 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies. CONCLUSION Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.
Collapse
Affiliation(s)
- Ana Zabalza
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Georgina Arrambide
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Susana Otero-Romero
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Preventive Medicine and Epidemiology Department, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Agustín Pappolla
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Paula Tagliani
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Samuel López-Maza
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Simón Cárdenas-Robledo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Juliana Esperalba
- Microbiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Candela Fernández-Naval
- Microbiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Monica Martínez-Gallo
- Immunology Division, Hospital Universitari Vall d'Hebron and Diagnostic Immunology Research Group, Valld'Hebron Research Institute (VHIR), Barcelona, Spain
| | - Mireia Castillo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Mercè Bonastre
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Mireia Resina-Salles
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Jordina Bertran
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Marta Rodriguez-Barranco
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Pere Carbonell-Mirabent
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Marina Gonzalez
- Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr, Josep Trueta Hospital and Santa Caterina Hospital, Girona, Spain Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain
| | - Miguel Merchan
- Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr, Josep Trueta Hospital and Santa Caterina Hospital, Girona, Spain Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain
| | - Ana Quiroga-Varela
- Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Albert Miguela
- Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain
| | - Imma Gómez
- Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain
| | - Gary Álvarez
- Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr, Josep Trueta Hospital and Santa Caterina Hospital, Girona, Spain Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain
| | - René Robles
- Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr, Josep Trueta Hospital and Santa Caterina Hospital, Girona, Spain Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain Medical Sciences Department, University of Girona, Girona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Dúnia Perez Del Campo
- Girona Clinical Laboratory, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain
| | - Xavier Queralt
- Girona Clinical Laboratory, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain
| | - Maria José Soler
- Department of Nephrology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Irene Agraz
- Department of Nephrology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Fernando Martinez-Valle
- Department of Internal Medicine, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Breogán Rodríguez-Acevedo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Luciana Midaglia
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Ángela Vidal-Jordana
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Álvaro Cobo-Calvo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Carmen Tur
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Ingrid Galan
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Joaquín Castillo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Jordi Río
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Carmen Espejo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Manuel Comabella
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Carlos Nos
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Jaume Sastre-Garriga
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Lluís Ramió-Torrentà
- Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr, Josep Trueta Hospital and Santa Caterina Hospital, Girona, Spain Neurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain Medical Sciences Department, University of Girona, Girona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Mar Tintoré
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| | - Xavier Montalban
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain
| |
Collapse
|
12
|
Chacon Alberty L, Curty E, Castillo M, Hochman-Mendez C, Looor G. miRNA and mRNA Interaction in Circulating Exosomes from Patients with Primary Graft Dysfunction After Lung Transplantation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
13
|
Meglia G, Castillo M, Cerutti D, Gomez M, Tortone C, Gastaldo M, Elena S, Ardoino S, Franco C, Bagnat E. Immunized Goat with a Conjunctival Vaccine Prevent the Abortus Despite Revaccination with the Same Strain. Int J Infect Dis 2022. [DOI: 10.1016/j.ijid.2021.12.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
14
|
Zabalza A, Arrambide G, Tagliani P, Cárdenas-Robledo S, Otero-Romero S, Esperalba J, Fernandez-Naval C, Trocoli Campuzano J, Martínez Gallo M, Castillo M, Bonastre M, Resina Sallés M, Beltran J, Carbonell-Mirabent P, Rodríguez-Barranco M, López-Maza S, Melgarejo Otálora PJ, Ruiz-Ortiz M, Pappolla A, Rodríguez Acevedo B, Midaglia L, Vidal-Jordana A, Cobo-Calvo A, Tur C, Galán I, Castilló J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Tintore M, Montalban X. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 2022; 9:9/2/e1143. [PMID: 35105687 PMCID: PMC8808353 DOI: 10.1212/nxi.0000000000001143] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 12/21/2021] [Indexed: 01/22/2023]
Abstract
Background and Objectives Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS. Methods This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2. Results A total of 121 (83.45%) of 145 PwMS were seropositive, and 25/42 (59.5%) presented a cellular response up to 13.1 months after COVID-19. Anti–CD20-treated patients had lower antibody titers than those under other DMTs (p < 0.001), but severe COVID-19 and a longer time from last infusion increased the likelihood of producing a humoral response. IFN-γ levels did not differ among DMT. Five of 7 (71.4%) anti-–CD20-treated seronegative patients had a cellular response. The humoral response persisted for more than 6 months in 41/56(81.13%) PwMS. In multivariate analysis, seropositivity decreased due to anti-CD20 therapy (OR 0.08 [95% CI 0.01–0.55]) and increased in males (OR 3.59 [1.02–12.68]), whereas the cellular response decreased in those with progressive disease (OR 0.04 [0.001–0.88]). No factors were associated with antibody persistence. Discussion Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti–CD20-treated patients, even in the absence of antibodies.
Collapse
|
15
|
Cobo-Calvo A, Zabalza A, Río J, Arrambide G, Otero-Romero S, Tagliani P, Cárdenas-Robledo S, Castillo M, Espejo C, Rodriguez M, Carbonell P, Rodríguez B, Midaglia L, Vidal-Jordana Á, Tur C, Galan I, Castillo J, Comabella M, Nos C, Auger C, Tintoré M, Rovira À, Montalban X, Sastre-Garriga J. Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. J Neurol 2022; 269:1773. [PMID: 35192034 PMCID: PMC8861609 DOI: 10.1007/s00415-022-11019-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- Alvaro Cobo-Calvo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
| | - Ana Zabalza
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Jordi Río
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Georgina Arrambide
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Susana Otero-Romero
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Paula Tagliani
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Simón Cárdenas-Robledo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Mireia Castillo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Carmen Espejo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Marta Rodriguez
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Pere Carbonell
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Breogán Rodríguez
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Luciana Midaglia
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Ángela Vidal-Jordana
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Carmen Tur
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Ingrid Galan
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Joaquín Castillo
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Manuel Comabella
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Carlos Nos
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Cristina Auger
- Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology (IDI), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Mar Tintoré
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Àlex Rovira
- Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology (IDI), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Xavier Montalban
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Jaume Sastre-Garriga
- Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Edifici Cemcat, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| |
Collapse
|
16
|
Castillo M, Posilio L, Rodriguez-Ruiz A, Chevalier M. Synthetic 2D mammography: 4AFC experiment for image quality evaluation. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00460-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
17
|
Affiliation(s)
- C Zamora
- Division of Neuroradiology, Department of RadiologyUniversity of North Carolina School of MedicineChapel Hill, North Carolina
| | - M Castillo
- Division of Neuroradiology, Department of RadiologyUniversity of North Carolina School of MedicineChapel Hill, North Carolina
| |
Collapse
|
18
|
Saba L, Brinjikji W, Spence JD, Wintermark M, Castillo M, Borst GJD, Yang Q, Yuan C, Buckler A, Edjlali M, Saam T, Saloner D, Lal BK, Capodanno D, Sun J, Balu N, Naylor R, Lugt AVD, Wasserman BA, Kooi ME, Wardlaw J, Gillard J, Lanzino G, Hedin U, Mikulis D, Gupta A, DeMarco JK, Hess C, Goethem JV, Hatsukami T, Rothwell P, Brown MM, Moody AR. Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement. AJNR Am J Neuroradiol 2021; 42:1566-1575. [PMID: 34326105 DOI: 10.3174/ajnr.a7223] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 01/26/2021] [Indexed: 12/19/2022]
Abstract
Current guidelines for primary and secondary prevention of stroke in patients with carotid atherosclerosis are based on the quantification of the degree of stenosis and symptom status. Recent publications have demonstrated that plaque morphology and composition, independent of the degree of stenosis, are important in the risk stratification of carotid atherosclerotic disease. This finding raises the question as to whether current guidelines are adequate or if they should be updated with new evidence, including imaging for plaque phenotyping, risk stratification, and clinical decision-making in addition to the degree of stenosis. To further this discussion, this roadmap consensus article defines the limits of luminal imaging and highlights the current evidence supporting the role of plaque imaging. Furthermore, we identify gaps in current knowledge and suggest steps to generate high-quality evidence, to add relevant information to guidelines currently based on the quantification of stenosis.
Collapse
Affiliation(s)
- L Saba
- From the Department of Radiology (L.S.), University of Cagliari, Cagliari, Italy
| | | | - J D Spence
- Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, Western University, London, Ontario, Canada
| | - M Wintermark
- Department of Neuroradiology (M.W.), Stanford University and Healthcare System, Stanford, California
| | - M Castillo
- Department of Radiology (M.C.), University of North Carolina, Chapel Hill, North Carolina
| | - G J D Borst
- Department of Vascular Surgery (G.J.D.B.), University Medical Center Utrecht, Utrecht, the Netherlands
| | - Q Yang
- Department of Radiology (Q.Y.), Xuanwu Hospital, Capital Medical University, Beijing, China
| | - C Yuan
- Departments of Radiology (C.Y., J.S., N.B.)
| | - A Buckler
- Elucid Bioimaging (A.B.), Boston, Massachusetts
| | - M Edjlali
- Department of Neuroradiology (M.E.), Université Paris-Descartes-Sorbonne-Paris-Cité, IMABRAIN-INSERM-UMR1266, DHU-Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - T Saam
- Department of Radiology (T.S.), University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.,Radiologisches Zentrum (T.S.), Rosenheim, Germany
| | - D Saloner
- Departments of Radiology and Biomedical Imaging (D.S., C.H.), University of California San Francisco, San Francisco, California
| | - B K Lal
- Department of Vascular Surgery (B.K.L.), University of Maryland School of Medicine, Baltimore, Maryland
| | - D Capodanno
- Division of Cardiology (D.C.), A.O.U. Policlinico "G. Rodolico-San Marco," University of Catania, Italy
| | - J Sun
- Departments of Radiology (C.Y., J.S., N.B.)
| | - N Balu
- Departments of Radiology (C.Y., J.S., N.B.)
| | - R Naylor
- The Leicester Vascular Institute (R.N.), Glenfield Hospital, Leicester, UK
| | - A V D Lugt
- Department of Radiology and Nuclear Medicine (A.v.d.L.), Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - B A Wasserman
- The Russell H. Morgan Department of Radiology and Radiological Science (B.A.W.), Johns Hopkins Hospital, Baltimore, Maryland
| | - M E Kooi
- Department of Radiology and Nuclear Medicine (M.E.K.), CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands
| | - J Wardlaw
- Centre for Clinical Brain Sciences (J.W.), United Kingdom Dementia Research Institute and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK
| | - J Gillard
- Christ's College (J.G.), Cambridge, UK
| | - G Lanzino
- Neurosurgery (G.L.) Mayo Clinic, Rochester, Minnesota
| | - U Hedin
- Department of Molecular Medicine and Surgery (U.H.), Karolinska Institutet, Stockholm, Sweden.,Department of Vascular Surgery (U.H.), Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
| | - D Mikulis
- Joint Department of Medical Imaging and the Functional Neuroimaging Laboratory (D.M.), University Health Network, Toronto, Ontario, Canada
| | - A Gupta
- Department of Radiology (A.G.), Weill Cornell Medical College, New York, New York
| | - J K DeMarco
- Walter Reed National Military Medical Center and Uniformed Services University of the Health Sciences (J.K.D.), Bethesda, Maryland
| | - C Hess
- Departments of Radiology and Biomedical Imaging (D.S., C.H.), University of California San Francisco, San Francisco, California
| | - J V Goethem
- Faculty of Biomedical Sciences (J.V.G.), University of Antwerp, Antwerp, Belgium
| | - T Hatsukami
- Surgery (T.H.), University of Washington, Seattle, Washington
| | - P Rothwell
- Centre for Prevention of Stroke and Dementia (P.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK
| | - M M Brown
- Stroke Research Centre (M.M.B.), Department of Brain Repair and Rehabilitation, University College of London Queen Square Institute of Neurology, University College London, UK
| | - A R Moody
- Department of Medical Imaging (A.R.M.), University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
19
|
Tielke J, Maas M, Castillo M, Rezwan K, Avila M. Statistical analysis of thermal conductivity experimentally measured in water-based nanofluids. Proc Math Phys Eng Sci 2021. [DOI: 10.1098/rspa.2021.0222] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Nanofluids are suspensions of nanoparticles in a base heat-transfer liquid. They have been widely investigated to boost heat transfer since they were proposed in the 1990s. We present a statistical correlation analysis of experimentally measured thermal conductivity of water-based nanofluids available in the literature. The influences of particle concentration, particle size, temperature and surfactants are investigated. For specific particle materials (alumina, titania, copper oxide, copper, silica and silicon carbide), separate analyses are performed. The conductivity increases with the concentration in qualitative agreement with Maxwell’s theory of homogeneous media. The conductivity also increases with the temperature (in addition to the improvement due to the increased conductivity of water). Surprisingly, only silica nanofluids exhibit a statistically significant effect of the particle size, whereby smaller particles lead to faster heat transfer. Overall, the large scatter in the experimental data prevents a compelling, unambiguous assessment of these effects. Taken together, the results of our analysis suggest that more comprehensive experimental characterizations of nanofluids are necessary to estimate their practical potential.
Collapse
Affiliation(s)
- J. Tielke
- University of Bremen, Center of Applied Space Technology and Microgravity (ZARM), Am Fallturm, 2, 28359 Bremen, Germany
| | - M. Maas
- University of Bremen, Advanced Ceramics, Am Biologischen Garten, 2, 28359 Bremen, Germany
- MAPEX Center for Materials and Processes, University of Bremen, 28359 Bremen, Germany
| | - M. Castillo
- University of Bremen, Center of Applied Space Technology and Microgravity (ZARM), Am Fallturm, 2, 28359 Bremen, Germany
| | - K. Rezwan
- University of Bremen, Advanced Ceramics, Am Biologischen Garten, 2, 28359 Bremen, Germany
- MAPEX Center for Materials and Processes, University of Bremen, 28359 Bremen, Germany
| | - M. Avila
- University of Bremen, Center of Applied Space Technology and Microgravity (ZARM), Am Fallturm, 2, 28359 Bremen, Germany
- MAPEX Center for Materials and Processes, University of Bremen, 28359 Bremen, Germany
| |
Collapse
|
20
|
Castillo-Montes A, Castillo M, Ardiles L. POS-308 Characterization of pre-clinical chronic kidney disase (sCKD) in the population of Chile. Kidney Int Rep 2021. [DOI: 10.1016/j.ekir.2021.03.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
21
|
Calvo-Barreiro L, Eixarch H, Cornejo T, Costa C, Castillo M, Mestre L, Guaza C, Martínez-Cuesta MDC, Tanoue T, Honda K, González-López JJ, Montalban X, Espejo C. Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. Neurotherapeutics 2021; 18:920-937. [PMID: 33829410 PMCID: PMC8423884 DOI: 10.1007/s13311-021-01016-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/26/2021] [Indexed: 11/24/2022] Open
Abstract
Gut microbiome studies in multiple sclerosis (MS) patients are unravelling some consistent but modest patterns of gut dysbiosis. Among these, a significant decrease of Clostridia cluster IV and XIVa has been reported. In the present study, we investigated the therapeutic effect of a previously selected mixture of human gut-derived 17 Clostridia strains, which belong to Clostridia clusters IV, XIVa, and XVIII, on the clinical outcome of experimental autoimmune encephalomyelitis (EAE). The observed clinical improvement was related to lower demyelination and astrocyte reactivity as well as a tendency to lower microglia reactivity/infiltrating macrophages and axonal damage in the central nervous system (CNS), and to an enhanced immunoregulatory response of regulatory T cells in the periphery. Transcriptome studies also highlighted increased antiinflammatory responses related to interferon beta in the periphery and lower immune responses in the CNS. Since Clostridia-treated mice were found to present higher levels of the immunomodulatory short-chain fatty acid (SCFA) butyrate in the serum, we studied if this clinical effect could be reproduced by butyrate administration alone. Further EAE experiments proved its preventive but slight therapeutic impact on CNS autoimmunity. Thus, this smaller therapeutic effect highlighted that the Clostridia-induced clinical effect was not exclusively related to the SCFA and could not be reproduced by butyrate administration alone. Although it is still unknown if these Clostridia strains will have the same effect on MS patients, gut dysbiosis in MS patients could be partially rebalanced by these commensal bacteria and their immunoregulatory properties could have a beneficial effect on MS clinical course.
Collapse
MESH Headings
- Animals
- Butyrates/administration & dosage
- Clostridiaceae/immunology
- Dysbiosis/immunology
- Dysbiosis/pathology
- Dysbiosis/therapy
- Encephalomyelitis, Autoimmune, Experimental/immunology
- Encephalomyelitis, Autoimmune, Experimental/pathology
- Encephalomyelitis, Autoimmune, Experimental/therapy
- Fatty Acids, Volatile/administration & dosage
- Female
- Gastrointestinal Microbiome/physiology
- Humans
- Mice
- Mice, Inbred C57BL
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/immunology
Collapse
Affiliation(s)
- Laura Calvo-Barreiro
- Servei de Neurologia-Neuroimmunologia, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Centre d'Esclerosi Múltiple de Catalunya, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain
| | - Herena Eixarch
- Servei de Neurologia-Neuroimmunologia, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Centre d'Esclerosi Múltiple de Catalunya, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain
| | - Thais Cornejo
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain
- Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Carme Costa
- Servei de Neurologia-Neuroimmunologia, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Centre d'Esclerosi Múltiple de Catalunya, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain
| | - Mireia Castillo
- Servei de Neurologia-Neuroimmunologia, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Centre d'Esclerosi Múltiple de Catalunya, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain
| | - Leyre Mestre
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain
- Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Avda. Doctor Arce 37, 28002, Madrid, Spain
| | - Carmen Guaza
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain
- Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Avda. Doctor Arce 37, 28002, Madrid, Spain
| | - María Del Carmen Martínez-Cuesta
- Department of Food Biotechnology and Microbiology, Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC-UAM), C/ Nicolás Cabrera 9, 28049, Madrid, Spain
| | - Takeshi Tanoue
- RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan
| | - Kenya Honda
- RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan
| | - Juan José González-López
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain
- Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Xavier Montalban
- Servei de Neurologia-Neuroimmunologia, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Centre d'Esclerosi Múltiple de Catalunya, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain
| | - Carmen Espejo
- Servei de Neurologia-Neuroimmunologia, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Centre d'Esclerosi Múltiple de Catalunya, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
- Universitat Autònoma de Barcelona, 08193, Bellaterra Cerdanyola del Vallès, Spain.
- Red Española de Esclerosis Múltiple (REEM), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo de Investigación Sanitaria, Madrid, Spain.
| |
Collapse
|
22
|
Vidal P, Cepas Guillen P, Caldentey G, Martinez Gomez E, Borrego-Rodriguez J, Echarte Morales J, Minguito Carazo C, Alonso Orcajo N, Llagostera M, Castillo M, Viana Tejedor A, Quiroga X, Freixa X, Fernandez-Vazquez F, Sabate M. Acute coronary syndromes in nonagenarians: do we have reliable risk scores? Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
GRACE score is strongly validated to determine the probability of death in acute coronary syndrome (ACS), nevertheless its usefulness in nonagenarians, a population with frequently associated comorbidities, is less stablished. BARTHEL and CHARLSON scores might be useful tools to predict outcomes in this population.
Objective
The aim of this study was to evaluate the potential applicability of GRACE score and two comorbidity scores (CHARLSON and BARTHEL) to estimate prognosis in nonagenarians with ACS.
Material and methods
We retrospectively included all consecutive patients equal to or older than 90 years old admitted with non-ST (NSTEMI) or ST segment elevation myocardial infarction (STEMI) in four tertiary care centers between 2005 and 2018. Patients with type 2 myocardial infarction were excluded. We collected patients' baseline characteristics and procedural data. In-hospital and at 1-year follow-up all-cause and cardiovascular mortality were assessed. Risk score accuracy was evaluated by area under the curve ROC (AUC).
Results
A total of 444 patients (mean age 92.6±2.4 years, 60% females) were analyzed.
Approximately half of them (n=241, 54%) with STEMI and the remainder (n=203, 46%) with NSTEMI. Global GRACE-AUC for in-hospital and 1-year all-cause mortality were moderate (0.64; 95% CI: 0.59–0.69 and 0.62; 95% CI: 0.57–0.67, respectively). Only in the NSTEMI group, the GRACE-AUC was better to predict in-hospital mortality, 0.70 (95% CI: 0.63–0.77). Neither CHARLSON nor BARTHEL showed better predictive results than GRACE score (AUC ≤0.60).
Conclusion
GRACE score has moderate accuracy to estimate mortality in nonagenarian patients with ACS. BARTHEL and CHARLSON scores do not improve the predictive value of GRACE score. An individualized approach is required to make therapeutic decisions in this special population.
Figure 1. ROC-GRACE curves
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- P Vidal
- Hospital Clinic de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | | | | - M Castillo
- Hospital Clinic de Barcelona, Barcelona, Spain
| | | | | | - X Freixa
- Hospital Clinic de Barcelona, Barcelona, Spain
| | | | - M Sabate
- Hospital Clinic de Barcelona, Barcelona, Spain
| |
Collapse
|
23
|
Eixarch H, Calvo-Barreiro L, Costa C, Reverter-Vives G, Castillo M, Gil V, Del Río JA, Montalban X, Espejo C. Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis. Neurotherapeutics 2020; 17:1988-2003. [PMID: 32681355 PMCID: PMC7851289 DOI: 10.1007/s13311-020-00885-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Bone morphogenetic proteins (BMPs) are secreted growth factors that belong to the transforming growth factor beta superfamily. BMPs have been implicated in physiological processes, but they are also involved in many pathological conditions. Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS); however, its etiology remains elusive. Some evidence points to BMPs as important players in the pathogenesis of inflammatory and autoimmune disorders. In the present work, we studied the expression of BMP2, BMP4, BMP5, BMP6, BMP7, BMP type II receptor, and noggin in the immune system during different phases of experimental autoimmune encephalomyelitis (EAE). Major changes in the expression of BMPs took place in the initial phases of EAE. Indeed, those changes mainly affected BMP6 (whose expression was abrogated), BMP2, and BMP7 (whose expression was increased). In addition, we showed that in vivo inhibition of the BMP signaling pathway with small molecules ameliorated the already established clinical symptoms of EAE, as well as the CNS histopathological features. At the immune level, we observed an expansion of plasmacytoid dendritic cells (pDCs) in mice treated with small molecules that inhibit the BMP signaling pathway. pDCs could play an important role in promoting the expansion of antigen-specific regulatory T cells. Altogether, our data suggest a role for BMPs in early immune events that take place in myelin oligodendrocyte glycoprotein (MOG)-induced EAE. In addition, the clinical outcome of the disease was improved when the BMP signaling pathway was inhibited in mice that presented established EAE symptoms.
Collapse
Affiliation(s)
- Herena Eixarch
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra (Cerdanyola del Vallès), Spain
| | - Laura Calvo-Barreiro
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra (Cerdanyola del Vallès), Spain
| | - Carme Costa
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra (Cerdanyola del Vallès), Spain
| | - Gemma Reverter-Vives
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra (Cerdanyola del Vallès), Spain
| | - Mireia Castillo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra (Cerdanyola del Vallès), Spain
| | - Vanessa Gil
- Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Parc Científic de Barcelona, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - José Antonio Del Río
- Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Parc Científic de Barcelona, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Xavier Montalban
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Universitat Autònoma de Barcelona, 08193, Bellaterra (Cerdanyola del Vallès), Spain
- Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Canada
| | - Carmen Espejo
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Universitat Autònoma de Barcelona, 08193, Bellaterra (Cerdanyola del Vallès), Spain.
| |
Collapse
|
24
|
Franceschi AM, Arora R, Wilson R, Giliberto L, Libman RB, Castillo M. Neurovascular Complications in COVID-19 Infection: Case Series. AJNR Am J Neuroradiol 2020; 41:1632-1640. [PMID: 32527844 PMCID: PMC7583125 DOI: 10.3174/ajnr.a6655] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Accepted: 05/22/2020] [Indexed: 01/28/2023]
Abstract
We present a series of 10 hospitalized patients with confirmed coronavirus 2019 infections who developed severe neurovascular complications and discuss the possible reasons for these findings and their relationship to the novel Severe Acute Respiratory Syndrome coronavirus 2 infection.
Collapse
Affiliation(s)
| | - R Arora
- Departments of Radiology and Neurology (R.A., L.G., R.B.L.), Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, New York
| | - R Wilson
- Neuroradiology Section (R.W., M.C.), Department of Radiology, The University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - L Giliberto
- Departments of Radiology and Neurology (R.A., L.G., R.B.L.), Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, New York
| | - R B Libman
- Departments of Radiology and Neurology (R.A., L.G., R.B.L.), Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, New York
| | - M Castillo
- Neuroradiology Section (R.W., M.C.), Department of Radiology, The University of North Carolina School of Medicine, Chapel Hill, North Carolina
| |
Collapse
|
25
|
Toh CH, Castillo M, Wei KC, Chen PY. MRS as an Aid to Diagnose Malignant Transformation in Low-Grade Gliomas with Increasing Contrast Enhancement. AJNR Am J Neuroradiol 2020; 41:1592-1598. [PMID: 32732270 DOI: 10.3174/ajnr.a6688] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 06/04/2020] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Increased contrast enhancement has been used as a marker of malignant transformation in low-grade gliomas. This marker has been found to have limited accuracy because many low-grade gliomas with increased contrast enhancement remain grade II. We aimed to investigate whether MR spectroscopy can contribute to the diagnosis of malignant transformation in low-grade gliomas with increased contrast enhancement. MATERIALS AND METHODS Patients with low-grade gliomas who had contemporaneous MR spectroscopy and histopathology for tumor regions with increased contrast enhancement between 2004 and 2015 were retrospectively reviewed. Clinical data collected were sex and age, Karnofsky Performance Scale, histologic subtypes, isocitrate dehydrogenase 1 mutation status, disease duration, adjuvant therapy, and post-radiation therapy duration. Imaging data collected were contrast-enhancement size, whole-tumor size, MR spectroscopy metabolite ratios, and tumor grades of regions with increased contrast enhancement. Diagnostic values of these factors on malignant transformation of low-grade gliomas were statistically analyzed. RESULTS A total of 86 patients with 96 MR spectroscopy studies were included. Tumor grades associated with increased contrast enhancement were grade II (n = 42), grade III (n = 27), and grade IV (n = 27). On multivariate analysis, the NAA/Cho ratio was the only significant factor (P < .001; OR, 7.1; 95% CI, 3.2-16.1) diagnostic of malignant transformation. With 0.222 as the cutoff value, the sensitivity, specificity, and accuracy of NAA/Cho for diagnosing malignant transformation were 94.4%, 83.3%, and 89.6%, respectively. CONCLUSIONS MR spectroscopy complements conventional MR imaging in the diagnosis of malignant transformation in a subgroup of low-grade gliomas with increased contrast enhancement.
Collapse
Affiliation(s)
- C H Toh
- From the Departments of Medical Imaging and Intervention (C.H.T.)
| | - M Castillo
- Department of Radiology (M.C.), University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - K-C Wei
- Neurosurgery (K.-C.W., P.-Y.C.), Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Tao-Yuan, Taiwan
| | - P-Y Chen
- Neurosurgery (K.-C.W., P.-Y.C.), Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Tao-Yuan, Taiwan
| |
Collapse
|
26
|
Moreno Mochi P, Vargas JM, Vivaldo S, Bottiglieri M, López C, Mochi S, Cobos M, Castillo M, Del Campo R, Jure MA. Molecular epidemiology of methicillin-resistant Staphylococcus aureus from different population groups in Argentina. J Glob Antimicrob Resist 2020; 23:82-86. [PMID: 32763358 DOI: 10.1016/j.jgar.2020.07.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2019] [Revised: 07/07/2020] [Accepted: 07/17/2020] [Indexed: 12/01/2022] Open
Abstract
OBJECTIVES In Latin America, methicillin-resistantStaphylococcus aureus (MRSA) is a leading cause of nosocomial infections. Limited studies have addressed the molecular epidemiology of MRSA clones in Argentina, characterised by continuous human migratory movements. The aim of this study was to describe the MRSA epidemiology, including distinct patient populations from different regions of the country. METHODS MRSA strains were collected in epidemiological studies conducted from 2009 to 2015 in three cities (Formosa, Córdoba and Tucumán) and involving four population groups: community adult patients; hospitalised adults; hospitalised children; and healthy children (nasal colonisation). Antimicrobial susceptibility testing, SCCmec and Panton-Valentine leukocidin (PVL) typing, pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) were performed. RESULTS A total of 120 MRSA isolates were recovered with an important population diversity in the groups studied; in community adult patients, MRSA isolates corresponded to ST5, ST267 and ST1619; from hospitalised adults they were ST97, ST5, ST72, ST125, ST200, ST647, ST747, ST935 and ST2941; from hospitalised children they were ST5, ST30, ST34, ST1163 and ST1619; and from colonised children they were ST5, ST125, ST34, ST100, ST1619, ST207 and ST1163. Results of SCCmec typing showed SCCmec I, SCCmec IIIA, SCCmec IV and SCCmec ND associated or not with PVL genes. CONCLUSIONS MRSA genetic lineages have differing distribution in the three regions. The most prevalent was ST5 in colonisation, community and invasive settings. Here we describe ST34-SCCmec IV clone for the first time in the hospitalised paediatric population. These findings contribute to the understanding of epidemiological changes in recent years.
Collapse
Affiliation(s)
- P Moreno Mochi
- Cátedra de Bacteriologia, Instituto de Microbiología Luis C. Verna, Fac. de Bioqcam, Qca y Fcia, Universidad Nacional de Tucumán, Ayacucho 491, San Miguel de Tucumán CP 4000, Argentina
| | - J M Vargas
- Cátedra de Bacteriologia, Instituto de Microbiología Luis C. Verna, Fac. de Bioqcam, Qca y Fcia, Universidad Nacional de Tucumán, Ayacucho 491, San Miguel de Tucumán CP 4000, Argentina
| | - S Vivaldo
- Hospital de la Madre y el Niño, Córdoba 1450, Formosa, CP 3600, Argentina
| | - M Bottiglieri
- Clínica Universitaria Reina Fabiola-Fundación para el Progreso de la UCC, Oncativo 1248, Córdoba, CP 5000, Argentina
| | - C López
- Centro de Microbiología Médica, Rondeau 877, San Miguel de Tucumán CP4000, Argentina
| | - S Mochi
- Hospital Ángel Cruz Padilla, Alberdi 540, San Miguel de Tucumán CP4000, Argentina
| | - M Cobos
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal, and Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, Spain
| | - M Castillo
- Cátedra de Bacteriologia, Instituto de Microbiología Luis C. Verna, Fac. de Bioqcam, Qca y Fcia, Universidad Nacional de Tucumán, Ayacucho 491, San Miguel de Tucumán CP 4000, Argentina
| | - R Del Campo
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal, and Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, Spain
| | - M A Jure
- Cátedra de Bacteriologia, Instituto de Microbiología Luis C. Verna, Fac. de Bioqcam, Qca y Fcia, Universidad Nacional de Tucumán, Ayacucho 491, San Miguel de Tucumán CP 4000, Argentina.
| |
Collapse
|
27
|
Franceschi AM, Ahmed O, Giliberto L, Castillo M. Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection. AJNR Am J Neuroradiol 2020; 41:1173-1176. [PMID: 32439646 DOI: 10.3174/ajnr.a6595] [Citation(s) in RCA: 162] [Impact Index Per Article: 40.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2020] [Accepted: 04/24/2020] [Indexed: 01/11/2023]
Abstract
We describe 2 hospitalized patients with confirmed coronavirus 19 (COVID-19) infection in whom brain imaging showed hemorrhagic posterior reversible encephalopathy syndrome, and we discuss the possible reasons for these findings and their relationship to the infection.
Collapse
Affiliation(s)
- A M Franceschi
- From the Neuroradiology Section, Department of Radiology (A.M.F.)
| | - O Ahmed
- Department of Radiology (O.A.), Stony Brook University Hospital, Stony Brook, New York
| | - L Giliberto
- Department of Neurology (L.G.), Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, New York
| | - M Castillo
- Neuroradiology Section, Department of Radiology (M.C.), University of North Carolina School of Medicine, Chapel Hill, North Carolina
| |
Collapse
|
28
|
Zohrabian VM, Staib LH, Castillo M, Wang L. Scientific Collaboration across Time and Space: Bibliometric Analysis of the American Journal of Neuroradiology, 1980-2018. AJNR Am J Neuroradiol 2020; 41:766-771. [PMID: 32299800 DOI: 10.3174/ajnr.a6523] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 03/02/2020] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Scientific collaboration is traditionally acknowledged through coauthorship. Studies on this topic are few in the neuroimaging literature. This study is a bibliometric analysis of the American Journal of Neuroradiology (AJNR) between 1980 and 2018, with the primary aim of evaluating changes in article collaboration. MATERIALS AND METHODS Full bibliographic records from 1980 to 2018 were retrieved. Yearly metrics calculated included the number of articles published, the average number of authors, and the average number of affiliations per article. The levels of evidence of 160 random articles were determined. Geographic characteristics of author affiliations were analyzed. Changes across time were evaluated using linear regression, while Spearman rank-order correlation was used to determine relationships between level of evidence and time, number of authors, and number of affiliations. RESULTS There was a steady linear growth in the number of articles (R 2 = 0.70, P < 1e-10) from 1980 to 2018. There were clear linear increases in the average number of authors (R 2 = 0.91, P < 1e-15) and affiliations (R 2 = 0.90, P < 1e-15) per article. There was a significant correlation between level of evidence and time period (Spearman ρ = -0.42, P < 1e-7), indicating that articles trended toward better methodologic quality or strength of results over time. A significant correlation existed between the level of evidence and the number of authors (Spearman ρ = -0.39, P < 1e-6). There were linear increases in the average number of different geographic locales of authors per article by country/region (R 2 = 0.80, P < 1e-13), state/province (R 2 = 0.88, P < 1e-15), and locality/city/town (R 2 = 0.86, P < 1e-15). CONCLUSIONS From 1980 to 2018, as the quantity of articles published in the AJNR increased, their level of evidence improved, while an increasing number of authors with different affiliations and from different geographic locales collaborated on these articles.
Collapse
Affiliation(s)
- V M Zohrabian
- From the Department of Radiology and Biomedical Imaging (V.M.Z., L.H.S.), Yale School of Medicine, New Haven, Connecticut
| | - L H Staib
- From the Department of Radiology and Biomedical Imaging (V.M.Z., L.H.S.), Yale School of Medicine, New Haven, Connecticut
| | - M Castillo
- Department of Radiology (M.C.), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - L Wang
- Cushing/Whitney Medical Library (L.W.), Yale University, New Haven, Connecticut
| |
Collapse
|
29
|
Sousa Félix C, Chaves Marques S, Bispo M, Castillo M, Bana E Costa T, Chagas C. A Pancreatic Cyst Leading to Obstructive Jaundice. GE Port J Gastroenterol 2020; 27:446-448. [PMID: 33251297 DOI: 10.1159/000507203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Accepted: 01/20/2020] [Indexed: 11/19/2022]
Affiliation(s)
- Catarina Sousa Félix
- Gastroenterology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
| | | | - Miguel Bispo
- Gastroenterology Department, Champalimaud Foundation, Lisbon, Portugal
| | - Mireia Castillo
- Pathology Department, Champalimaud Foundation, Lisbon, Portugal
| | - Tiago Bana E Costa
- Gastroenterology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
| | - Cristina Chagas
- Gastroenterology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
| |
Collapse
|
30
|
Calvo-Barreiro L, Eixarch H, Ponce-Alonso M, Castillo M, Lebrón-Galán R, Mestre L, Guaza C, Clemente D, del Campo R, Montalban X, Espejo C. A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. Cells 2020; 9:cells9040906. [PMID: 32272791 PMCID: PMC7226819 DOI: 10.3390/cells9040906] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 03/28/2020] [Accepted: 04/03/2020] [Indexed: 02/06/2023] Open
Abstract
Previous studies in experimental autoimmune encephalomyelitis (EAE) models have shown that some probiotic bacteria beneficially impact the development of this experimental disease. Here, we tested the therapeutic effect of two commercial multispecies probiotics—Lactibiane iki and Vivomixx—on the clinical outcome of established EAE. Lactibiane iki improves EAE clinical outcome in a dose-dependent manner and decreases central nervous system (CNS) demyelination and inflammation. This clinical improvement is related to the inhibition of pro-inflammatory and the stimulation of immunoregulatory mechanisms in the periphery. Moreover, both probiotics modulate the number and phenotype of dendritic cells (DCs). Specifically, Lactibiane iki promotes an immature, tolerogenic phenotype of DCs that can directly induce immune tolerance in the periphery, while Vivomixx decreases the percentage of DCs expressing co-stimulatory molecules. Finally, gut microbiome analysis reveals an altered microbiome composition related to clinical condition and disease progression. This is the first preclinical assay that demonstrates that a commercial probiotic performs a beneficial and dose-dependent effect in EAE mice and one of the few that demonstrates a therapeutic effect once the experimental disease is established. Because this probiotic is already available for clinical trials, further studies are being planned to explore its therapeutic potential in multiple sclerosis patients.
Collapse
Affiliation(s)
- Laura Calvo-Barreiro
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya, Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (L.C.-B.); (H.E.); (M.C.); (X.M.)
- Universitat Autònoma de Barcelona, 08193 Bellaterra, Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
| | - Herena Eixarch
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya, Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (L.C.-B.); (H.E.); (M.C.); (X.M.)
- Universitat Autònoma de Barcelona, 08193 Bellaterra, Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
| | - Manuel Ponce-Alonso
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal, and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera de Colmenar km. 9.1, 28034 Madrid, Spain; (M.P.-A.); (R.d.C.)
| | - Mireia Castillo
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya, Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (L.C.-B.); (H.E.); (M.C.); (X.M.)
- Universitat Autònoma de Barcelona, 08193 Bellaterra, Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
| | - Rafael Lebrón-Galán
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
- Grupo de Neuroinmuno-Reparación, Unidad de Investigación, Hospital Nacional de Parapléjicos, Finca “La Peraleda” s/n, 45071 Toledo, Spain
| | - Leyre Mestre
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
- Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Avenida Doctor Arce 37, 28002 Madrid, Spain
| | - Carmen Guaza
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
- Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Avenida Doctor Arce 37, 28002 Madrid, Spain
| | - Diego Clemente
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
- Grupo de Neuroinmuno-Reparación, Unidad de Investigación, Hospital Nacional de Parapléjicos, Finca “La Peraleda” s/n, 45071 Toledo, Spain
| | - Rosa del Campo
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal, and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera de Colmenar km. 9.1, 28034 Madrid, Spain; (M.P.-A.); (R.d.C.)
| | - Xavier Montalban
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya, Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (L.C.-B.); (H.E.); (M.C.); (X.M.)
- Universitat Autònoma de Barcelona, 08193 Bellaterra, Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
- Division of Neurology, University of Toronto, St. Michael’s Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada
| | - Carmen Espejo
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya, Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (L.C.-B.); (H.E.); (M.C.); (X.M.)
- Universitat Autònoma de Barcelona, 08193 Bellaterra, Cerdanyola del Vallès, Spain
- Red Española de Esclerosis Múltiple (REEM), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 28801 Madrid, Spain; (R.L.-G.); (L.M.); (C.G.); (D.C.)
- Correspondence: ; Tel.: +34-93-489-3599
| |
Collapse
|
31
|
Ripolles-Avila C, Ramos-Rubio M, Hascoët AS, Castillo M, Rodríguez-Jerez JJ. New approach for the removal of mature biofilms formed by wild strains of Listeria monocytogenes isolated from food contact surfaces in an Iberian pig processing plant. Int J Food Microbiol 2020; 323:108595. [PMID: 32224347 DOI: 10.1016/j.ijfoodmicro.2020.108595] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 02/20/2020] [Accepted: 03/18/2020] [Indexed: 12/15/2022]
Abstract
One of the main objectives of the food industry is to guarantee food safety by providing innocuous food products. Therefore, this sector must consider all the possible biotic or abiotic contamination routes from the entry of raw materials to the release of the final product. Currently, one important problem in this regard is the presence of biofilms on food contact surfaces which can transmit pathogens such as L. monocytogenes. In industrial conditions biofilms are found in a mature state, so it is essential that when carrying out removal effectiveness studies in vitro the tests are realized with models that produce these structures in a similarly mature state. The main objective of this study was to evaluate the effectiveness of an alternative treatment (i.e. enzymatic detergent that include natural antimicrobial agents) and a conventional treatment (i.e. chlorinated alkaline) for the elimination of mature L. monocytogenes biofilms. The results showed a cell detachment from the formed mature biofilms with an effectivity of between 74.75%-97.73% and 53.94%-94.02% for the enzymatic treatment and the chlorinated alkaline detergent, respectively. On a qualitative level, it was observed that the dispersion in the structure was much higher for the enzymatic treatment than for the chlorinated alkaline, which continued to show obvious structure integrity. All this leads to the conclusion that treatments with an enzymatic detergent have a significantly greater impact on the removal of mature L. monocytogenes biofilms, although a further disinfection process would be needed, enhancing even more the treatment effectivity. This may imply that the industrial approach to addressing this problem should be modified to include new perspectives that are more effective than traditional ones.
Collapse
Affiliation(s)
- C Ripolles-Avila
- Area of Human Nutrition and Food Science, Departament de Ciència Animal i dels Aliments, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), CP 08193 Barcelona, Spain
| | - M Ramos-Rubio
- Area of Human Nutrition and Food Science, Departament de Ciència Animal i dels Aliments, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), CP 08193 Barcelona, Spain
| | - A S Hascoët
- Area of Human Nutrition and Food Science, Departament de Ciència Animal i dels Aliments, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), CP 08193 Barcelona, Spain
| | - M Castillo
- Area of Human Nutrition and Food Science, Departament de Ciència Animal i dels Aliments, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), CP 08193 Barcelona, Spain
| | - J J Rodríguez-Jerez
- Area of Human Nutrition and Food Science, Departament de Ciència Animal i dels Aliments, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), CP 08193 Barcelona, Spain.
| |
Collapse
|
32
|
Ligeiro D, Rao M, Maia A, Castillo M, Beltran A, Maeurer M. B Cells in the Gastrointestinal Tumor Microenvironment with a Focus on Pancreatic Cancer: Opportunities for Precision Medicine? Adv Exp Med Biol 2020; 1273:175-195. [PMID: 33119882 DOI: 10.1007/978-3-030-49270-0_10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We review state-of-the-art in translational and clinical studies focusing on the tumor microenvironment (TME) with a focus on tumor-infiltrating B cells (TIBs). The TME is a dynamic matrix of mutations, immune-regulatory networks, and distinct cell-to-cell interactions which collectively impact on disease progress. We discuss relevant findings concerning B cells in pancreatic cancer, the concepts of "bystander" B cells, the role of antigen-specific B cells contributing to augmenting anticancer-directed immune responses, the role of B cells as prognostic markers for response to checkpoint inhibitors (ICBs), and the potential use in adoptive cell tumor-infiltrating lymphocyte (TIL) products.
Collapse
Affiliation(s)
- Dário Ligeiro
- Immunogenetics Unit, Lisbon Centre for Blood and Transplantation (Instituto Português do Sangue e Transplantação, IPST), Lisbon, Portugal
| | - Martin Rao
- Immunosurgery Unit, Champalimaud Center for the Unknown, Lisbon, Portugal
| | - Andreia Maia
- Department of Pathology, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Mireia Castillo
- Department of Pathology, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Antonio Beltran
- Department of Pathology, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Markus Maeurer
- Immunosurgery Unit, Champalimaud Center for the Unknown, Lisbon, Portugal.
- I Med Clinical University of Mainz, Mainz, Germany.
| |
Collapse
|
33
|
Arranz I, Derbyshire M, Kroeger K, Mischke C, Stroka J, Anklam E, Biselli S, Boonzaaijer G, Burdaspal P, Castillo M, Clasen PE, de Rechter P, Dolan L, Fusari T, Glück B, Heide C, Herry MP, Hummert C, Koch P, Lauber U, Legarda MT, Lindberg H, Macho L, Moller T, Nørgaard A, Panagiotopoulou Y, Raga AC, Sizoo E, Sparrer D, Sweet P, Thielert G, Tsatsou-Dritsa A, Valdecanas B, van Egmond H, van Osenbruggen WA. Liquid Chromatographic Method for Quantitation of Patulin at 10 ng/mL in Apple-Based Products Intended for Infants: Interlaboratory Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/88.2.518] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
An interlaboratory trial for the determination of patulin in apple juice and fruit puree was conducted, involving 17 participants representing a cross section of industry, official food control, and research facilities. Mean recoveries reported ranged from 74 (10 ng/g) to 62% (25 ng/g) for apple juice and from 72 (25 ng/g) to 74% (10 ng/g) for fruit puree. Based on results for spiked samples (blind pairs at 2 levels), as well as naturally contaminated samples (blind pairs at 3 levels), the relative standard deviation for repeatability (RSDr) in juice ranged from 8.0 to 14.3% and in puree from 3.5 to 9.3%. The relative standard deviation for reproducibility (RSDR) in juice ranged from 19.8 to 39.5% and in puree from 12.5 to 35.2%, reflecting HORRAT values from 0.6 to 1.0 for juice and 0.4 to 0.9 for puree. The method showed acceptable within-laboratory and between-laboratory precision for each matrix, as required by current European legislation.
Collapse
Affiliation(s)
- Isabel Arranz
- Institute for Reference Materials and Measurements, Food Safety and Quality Unit, European Commission–Joint Research Centre, Retieseweg 111, B-2440 Geel, Belgium
| | - Michelle Derbyshire
- Institute for Reference Materials and Measurements, Food Safety and Quality Unit, European Commission–Joint Research Centre, Retieseweg 111, B-2440 Geel, Belgium
| | - Katy Kroeger
- Institute for Reference Materials and Measurements, Food Safety and Quality Unit, European Commission–Joint Research Centre, Retieseweg 111, B-2440 Geel, Belgium
| | - Carsten Mischke
- Institute for Reference Materials and Measurements, Food Safety and Quality Unit, European Commission–Joint Research Centre, Retieseweg 111, B-2440 Geel, Belgium
| | - Joerg Stroka
- Institute for Reference Materials and Measurements, Food Safety and Quality Unit, European Commission–Joint Research Centre, Retieseweg 111, B-2440 Geel, Belgium
| | - Elke Anklam
- Institute for Reference Materials and Measurements, Food Safety and Quality Unit, European Commission–Joint Research Centre, Retieseweg 111, B-2440 Geel, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Argiz L, Vega F, Castillo M, Pineda F, Blanco C. Selective Allergy to Conger Fish due to Parvalbumin. J Investig Allergol Clin Immunol 2019; 29:390-391. [DOI: 10.18176/jiaci.0412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
González-Pérez R, Pineda F, Poza-Guedes P, Castillo M, Matheu V, Sánchez-Machín I. Molecular Allergen Profiling of Dual Mite Sensitization in Severe Allergic Rhinitis. J Investig Allergol Clin Immunol 2019; 30:421-429. [PMID: 31530505 DOI: 10.18176/jiaci.0439] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Mites are the most prevalent source of indoor allergens. The present study used a component-resolved diagnosis (CRD) approach to investigate the mite-specific IgE sensitization profile for Dermatophagoides pteronyssinus and Blomia tropicalis. We also assessed the performance of a commercially available CRD approach in patients with severe allergic rhinitis. METHODS We selected 63 consecutive patients with dual sensitization to D pteronyssinus and B tropicalis and persistent severe rhinitis according to the ARIA guidelines. We performed skin prick tests with standardized extracts and determined specific serum IgE to both mites, along with serum specific IgE to Der p 1, Der p 2, Der p 23, Der p 10, and Blo t 5. RESULTS Fifty-eight and 59 patients had positive sIgE to the whole extracts of D pteronyssinus and B tropicalis, respectively. While 91.67% of patients were sensitized to specific IgE to Der p 1, Der p 2, and/or Der p 23, specific IgE to Blo t 5 (≥0.3 ISU-E) was not detected in most of the serum samples (55%). CONCLUSIONS Although the combination panel of the commercially available major allergens Der p 1, Der p 2, and Der p 23 identified more than 90% of the D pteronyssinus-allergic patients, Blo t 5 performed somewhat poorly in those sensitized to B tropicalis. Improvements in CRD and further research concerning the prevalence and clinical relevance of serodominant allergens are needed to achieve a genuine molecular diagnosis, as well as patient-centered mite allergy-specific immunotherapy.
Collapse
Affiliation(s)
- R González-Pérez
- Allergy Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - F Pineda
- Diater Laboratory, Madrid, Spain
| | - P Poza-Guedes
- Allergy Department, Hospital Universitario de Canarias, Tenerife, Spain
| | | | - V Matheu
- Allergy Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - I Sánchez-Machín
- Allergy Department, Hospital Universitario de Canarias, Tenerife, Spain
| |
Collapse
|
36
|
Castaneda CA, Castillo M, Torres-Cabala C, Bernabe LA, Casavilca S, Villegas V, Sanchez J, de la Cruz M, Dunstan J, Cotrina JM, Gomez HL, Chavez C, Landa-Baella MP, Tello K, Felix BF, Abugattas J. Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. Clin Transl Oncol 2019; 21:1127-1134. [PMID: 30778854 DOI: 10.1007/s12094-019-02033-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Accepted: 01/01/2019] [Indexed: 01/03/2023]
Abstract
PURPOSE This study aims to evaluate the association between composition of tumor-infiltrating lymphocytes (TIL) and expression of p16 in acral lentiginous melanoma (ALM), and their impact on prognosis. MATERIALS AND METHODS A cohort of 148 surgical pathology specimens of ALM was studied. TIL were evaluated by immunohistochemical detection of CD3 and CD8, along with CD20, CD4, CD68, and CD163 in a subset of 43 cases. p16 protein expression was also investigated in all the cases. RESULTS The median age was 66 years, median Breslow thickness was 6.0 mm, grade III TIL was found in 28.4% and lymph nodes were involved in 54.2%. Breslow thickness (p < 0.001), stage I-II (p < 0.001), negative lymph nodes (p < 0.001) and < 10% p16 (p = 0.01) were associated with longer survival. Grade III of TIL was associated with thinner Breslow thickness (p = 0.008) and lower mitosis (p = 0.047). A higher density of CD3 TIL was associated with male gender (p = 0.008), thinner Breslow thickness (p = 0.047), negative lymph node (p = 0.031), early stage (p = 0.046), and p16 nuclear expression of > 10% (p = 0.045). Higher CD8 TIL was associated with > p16 (p = 0.03). Survival analysis found that longer survival had a trend to be associated with high TIL (p = 0.090). Levels of CD3+ and CD8+ cells were correlated with those of CD4+, CD20+, CD68+ and CD163+ immune cells. CONCLUSIONS Higher levels of TIL tend to be associated with better overall survival in ALM. Loss of expression of p16 is associated with lower levels of CD3+ and CD8+ TIL, indicating a probable relationship between p16 and TIL immune response in ALM .
Collapse
Affiliation(s)
- C A Castaneda
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru.
- Faculty of Medicine, Universidad Privada San Juan Bautista, 15067, Lima, Peru.
| | - M Castillo
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - C Torres-Cabala
- Departments of Pathology and Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - L A Bernabe
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - S Casavilca
- Pathology Department, Instituto Nacional de Enfermedades Neoplasicas., Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - V Villegas
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - J Sanchez
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - M de la Cruz
- Breast Cancer Surgery Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - J Dunstan
- Breast Cancer Surgery Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - J M Cotrina
- Breast Cancer Surgery Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - H L Gomez
- Medical Oncology Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - C Chavez
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - M P Landa-Baella
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - K Tello
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - B F Felix
- Medical Oncology Department and Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| | - J Abugattas
- Breast Cancer Surgery Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, 15038, Lima, Peru
| |
Collapse
|
37
|
Aristizabal J, Puac P, Zamora C, Castillo M. Expected Findings and Complications After Tympanoplasty and Mastoidectomy. ACTA ACUST UNITED AC 2019. [DOI: 10.3174/ng.1800062] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
38
|
Reis de Sousa M, Santiago I, Barata MJ, Castillo M, Matos C. Intracholecystic papillary-tubular neoplasm in a patient with choledochal cyst and anomalous pancreaticobiliary junction: case report. BJR Case Rep 2019. [DOI: 10.1259/bjrcr.20180079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
A 75-year-old female incidentally presented with an enhancing intraluminal gallbladder mass, main bile duct dilatation and anomalous pancreaticobiliary junction (APBJ) during the staging of gastric adenocarcinoma. Histopathological analysis confirmed the diagnosis of intracholecystic papillary-tubular neoplasm. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder are rare gallbladder neoplasms, defined as intramucosal, preinvasive, exophytic, mass forming lesions. An association between choledochal cysts and anomalous pancreaticobiliary junction with gallbladder neoplasms is well known, and this case potentially illustrates gallbladder carcinogenesis related to these biliary anomalies.
Collapse
Affiliation(s)
- Marta Reis de Sousa
- Department of Radiology, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal
| | - Inês Santiago
- Department of Radiology, Fundação Champalimaud, Lisbon, Portugal
| | - Maria J Barata
- Department of Radiology, Fundação Champalimaud, Lisbon, Portugal
| | - Mireia Castillo
- Department of Pathology, Fundação Champalimaud, Lisbon, Portugal
| | - Celso Matos
- Department of Radiology, Fundação Champalimaud, Lisbon, Portugal
| |
Collapse
|
39
|
Espuch-Oliver A, Amaro-Gahete F, Silva JGDV, De-La-O A, Castillo M, Muñoz TDH. Effects of different exercise modalities on S-Klotho plasma levels in middle-aged sedentary adults. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.04.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Herrera DA, Ruge NO, Florez MM, Vargas SA, Ochoa-Escudero M, Castillo M. Neuroimaging Findings in Moebius Sequence. AJNR Am J Neuroradiol 2019; 40:862-865. [PMID: 30948378 DOI: 10.3174/ajnr.a6028] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Accepted: 03/12/2019] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Moebius sequence comprises a spectrum of brain congenital malformations predominantly affecting the function of multiple cranial nerves. Reported neuroimaging findings are heterogeneous and based on case reports or small case series. Our goal was to describe the neuroimaging findings of Moebius sequence in a large population of patients scanned with MR imaging. MATERIALS AND METHODS An observational cross-sectional study was performed to assess brain MR imaging findings in 38 patients with Moebius syndrome studied between 2013 and 2016. RESULTS Retrospective analysis of MR imaging studies showed flattening of the floor of the fourth ventricle floor secondary to a bilateral absent facial colliculus in 38 patients (100%) and unilateral absence in 1. A hypoplastic pons was found in 23 patients (60.5%). Mesencephalic malformations consisted of tectal beaking in 15 patients (39.5%) and increased anteroposterior midbrain diameter with a shallow interpeduncular cistern in 12 (31.6%). Infratentorial arachnoid cysts were found in 5 patients (13.2%), and cerebellar vermis hypoplasia, in 2 (5.3%). Supratentorial findings included the following: thalamic fusion (26.3%), periventricular nodular heterotopias (26.3%), ventriculomegaly (26.3%), callosal abnormalities (23.7%), and hippocampal malrotations (23.7%). CONCLUSIONS Findings seen in this large patient cohort agreed with previously published reports. Flattening of the fourth ventricle floor secondary to a bilaterally absent facial colliculus was the most frequent MR imaging finding. The presence of other brain stem and cerebellar malformations as well as supratentorial abnormalities may help explain clinical symptoms and achieve a correct diagnosis.
Collapse
Affiliation(s)
- D A Herrera
- From the Department of Radiology (D.A.H., M.M.F., S.A.V.)
| | - N O Ruge
- Grupo de Neurociencias (N.O.R.), Universidad de Antioquia, Medellín, Colombia
| | - M M Florez
- From the Department of Radiology (D.A.H., M.M.F., S.A.V.)
| | - S A Vargas
- From the Department of Radiology (D.A.H., M.M.F., S.A.V.)
| | - M Ochoa-Escudero
- Department of Radiology (M.O.-E.), Hospital Pablo Tobón Uribe, Medellín, Colombia
| | - M Castillo
- Department of Radiology (M.C.), University of North Carolina, Chapel Hill, North Carolina
| |
Collapse
|
41
|
Zamora C, Castillo M. Reply. AJNR Am J Neuroradiol 2019; 40:E16. [PMID: 30679210 DOI: 10.3174/ajnr.a5968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C Zamora
- Division of Neuroradiology, Department of Radiology University of North Carolina School of Medicine Chapel Hill, North Carolina
| | - M Castillo
- Division of Neuroradiology, Department of Radiology University of North Carolina School of Medicine Chapel Hill, North Carolina
| |
Collapse
|
42
|
Barbarroja-Escudero J, Sánchez-González MJ, Pineda F, Rodríguez-Rodríguez M, Castillo M, Alvarez-Mon M. Role of Creatine Kinase as an Allergen in Immediate Selective Allergy to Pork Meat. J Investig Allergol Clin Immunol 2019; 29:64-66. [DOI: 10.18176/jiaci.0333] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Rebaza LP, Galarreta JA, Castañeda C, Cotrina JM, Vilchez S, de la Cruz M, Ponce J, Aguilar A, Flores C, Castillo M, Galvez M, Vigil C. Abstract P2-14-12: Impact of the time interval between neoadjuvant chemotherapy and surgery in Latin-Americans breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-14-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Few studies have evaluated the impact of the time interval between neoadjuvant chemotherapy (NAC) and surgery in breast cancer. In Latin America, where the vast majority of hospitals are oversaturated, it is important to define which patients to give priority and to be clear about ideal time or maximum to schedule surgery after NAC without altering the prognosis. The objective of this work is to establish the ideal time interval for post-neoadjuvant surgery and evaluate the impact on patient survival.
Methods: We reviewed the clinical histories of breast cancer with clinical stage II and III who received NAC between 2005 and 2014. Patients were divided into 3 groups according to the time interval to surgery: <4, 4-8 and >8 weeks. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method, and comparisons of survival curves using the logrank or Breslow test, both globally and by molecular subtypes. The optimal time to surgery has been determined by the Cox model.
Results: During the study period, 583 patients who had post NA surgery before six months were registered. The median age was 49 years (range: 24-85), 82% had clinical stage III, 53% histological grade III, 32.7% were luminal A, 15.6% luminal B, 24.4% Her2 and 27.3% TN. According to the time interval to surgery, 67 (11.5%) patients had surgery before 4 weeks, 204 (35.0%) between 4 to 8 weeks, and 312 (53.5%) after 8 weeks. The groups do not present differences in relation to the clinical characteristics (p> 0.05). The median follow-up time was 4.8 years. The 5-year OS rate according to the time interval was 57.9, 61.5, and 62.7% (p = 0.581) and the RFS rate was 40.6, 52.3, and 51.1% (p = 0.411). No differences were found in the survival curves by molecular subtypes , except for luminal b like . In the multivariate analysis, the effect of the time interval to surgery was not significant in OS and RFS; however, the HR curve suggests that the appropriate cut-off point for surgical time would be 8 weeks.
Table 1:Time Interval :OS - RFS RFS OS MEDIAN5 - yearsPMEDIAN5 - yearsPWeeks for NAC to Surgery <4 weeks3.240.6 6.157.9 4-8 weeks6.352.3 9.161.5 >8 weeks5.151.10.416.762.70.581 Weeks for NAC to Surgery <8 weeks549.5 9.160.7 >8 weeks5.151.10.5856.762.70.414
Table 2 :Time Interval - Molecular Subtype RFS OS MEDIAN5 - yearsPMEDIAN5 - yearsPLUMINAL A LIKE < 8 weeks----74.1 ----84 >8 weeks7.163.80.719.973.90.236 *LUMINAL B LIKE < 8 weeks2.336.8 5.460.5 >8 weeks5.857.60.46----820.08 HER2 <8 weeks2.228.7 3.938.4 >8weeks3.645.90.57.26.261.30.616 TRIPLE NEGATIVE <8 weeks3.144.2 3.448.4 >8 weeks2.041.80.9143.743.90.516* ER + PR >20% KI67>14% , HER2 NEGATIVE
Conclusion: The time interval between the end of neoadjuvant period and surgery has no impact on recurrence-free survival or on overall survival, despite this we suggest that the period of time between neoadjuvant and surgery not be greater than 8 weeks. More studies will be required to determine the ideal time interval and which cases should be prioritized according to the characteristics of our patients.
Citation Format: Rebaza LP, Galarreta JA, Castañeda C, Cotrina JM, Vilchez S, de la Cruz M, Ponce J, Aguilar A, Flores C, Castillo M, Galvez M, Vigil C. Impact of the time interval between neoadjuvant chemotherapy and surgery in Latin-Americans breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-12.
Collapse
Affiliation(s)
- LP Rebaza
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - JA Galarreta
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - C Castañeda
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - JM Cotrina
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - S Vilchez
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - M de la Cruz
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - J Ponce
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - A Aguilar
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - C Flores
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - M Castillo
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - M Galvez
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - C Vigil
- ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| |
Collapse
|
44
|
Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol 2019; 30:236-242. [PMID: 30590484 DOI: 10.1093/annonc/mdy547] [Citation(s) in RCA: 101] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. PATIENTS AND METHODS We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. RESULTS A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. CONCLUSIONS TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.
Collapse
Affiliation(s)
- S J Luen
- Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia
| | - R Salgado
- Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium
| | - M V Dieci
- University of Padova, Padova, Italy; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - A Vingiani
- European Institute of Oncology IRCCS, Milan, Italy
| | - G Curigliano
- European Institute of Oncology IRCCS, Milan, Italy; University of Milano, Milan, Italy
| | - R E Gould
- MD Anderson Cancer Centre, Houston, USA
| | - C Castaneda
- Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
| | - T D'Alfonso
- Memorial Sloan Kettering Cancer Center, New York, USA
| | - J Sanchez
- Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
| | - E Cheng
- Department of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
| | - E Andreopoulou
- Department of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
| | - M Castillo
- Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
| | - S Adams
- New York University School of Medicine, New York, USA
| | - S Demaria
- Department of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
| | | | - S Michiels
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy, University Paris-Sud, University Paris-Saclay, Villejuif, France
| | - S Loi
- Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.
| |
Collapse
|
45
|
Abeysekara AU, Albert A, Alfaro R, Alvarez C, Álvarez JD, Arceo R, Arteaga-Velázquez JC, Avila Rojas D, Ayala Solares HA, Belmont-Moreno E, BenZvi SY, Brisbois C, Caballero-Mora KS, Capistrán T, Carramiñana A, Casanova S, Castillo M, Cotti U, Cotzomi J, Coutiño de León S, De León C, De la Fuente E, Díaz-Vélez JC, Dichiara S, Dingus BL, DuVernois MA, Ellsworth RW, Engel K, Espinoza C, Fang K, Fleischhack H, Fraija N, Galván-Gámez A, García-González JA, Garfias F, González-Muñoz A, González MM, Goodman JA, Hampel-Arias Z, Harding JP, Hernandez S, Hinton J, Hona B, Hueyotl-Zahuantitla F, Hui CM, Hüntemeyer P, Iriarte A, Jardin-Blicq A, Joshi V, Kaufmann S, Kar P, Kunde GJ, Lauer RJ, Lee WH, León Vargas H, Li H, Linnemann JT, Longinotti AL, Luis-Raya G, López-Coto R, Malone K, Marinelli SS, Martinez O, Martinez-Castellanos I, Martínez-Castro J, Matthews JA, Miranda-Romagnoli P, Moreno E, Mostafá M, Nayerhoda A, Nellen L, Newbold M, Nisa MU, Noriega-Papaqui R, Pretz J, Pérez-Pérez EG, Ren Z, Rho CD, Rivière C, Rosa-González D, Rosenberg M, Ruiz-Velasco E, Salesa Greus F, Sandoval A, Schneider M, Schoorlemmer H, Seglar Arroyo M, Sinnis G, Smith AJ, Springer RW, Surajbali P, Taboada I, Tibolla O, Tollefson K, Torres I, Vianello G, Villaseñor L, Weisgarber T, Werner F, Westerhoff S, Wood J, Yapici T, Yodh G, Zepeda A, Zhang H, Zhou H. Publisher Correction: Very-high-energy particle acceleration powered by the jets of the microquasar SS 433. Nature 2018; 564:E38. [PMID: 30482938 DOI: 10.1038/s41586-018-0688-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In this Letter, owing to a production error, the penultimate version of the PDF was published. The HTML version was always correct. The PDF has been corrected online.
Collapse
Affiliation(s)
- A U Abeysekara
- Department of Physics and Astronomy, University of Utah, Salt Lake City, UT, USA
| | - A Albert
- Physics and Theoretical Divisions, Los Alamos National Laboratory, Los Alamos, NM, USA
| | - R Alfaro
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - C Alvarez
- Universidad Autónoma de Chiapas, Tuxtla Gutiérrez, Mexico
| | - J D Álvarez
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico
| | - R Arceo
- Universidad Autónoma de Chiapas, Tuxtla Gutiérrez, Mexico
| | | | - D Avila Rojas
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - H A Ayala Solares
- Department of Physics, Pennsylvania State University, University Park, PA, USA
| | - E Belmont-Moreno
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - S Y BenZvi
- Department of Physics and Astronomy, University of Rochester, Rochester, NY, USA
| | - C Brisbois
- Department of Physics, Michigan Technological University, Houghton, MI, USA
| | | | - T Capistrán
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - A Carramiñana
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - S Casanova
- Institute of Nuclear Physics Polish Academy of Sciences, IFJ-PAN, Krakow, Poland.,Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - M Castillo
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico
| | - U Cotti
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico
| | - J Cotzomi
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - S Coutiño de León
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - C De León
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - E De la Fuente
- Departamento de Física, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Mexico
| | - J C Díaz-Vélez
- Departamento de Física, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Mexico.,Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, WI, USA
| | - S Dichiara
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - B L Dingus
- Physics and Theoretical Divisions, Los Alamos National Laboratory, Los Alamos, NM, USA
| | - M A DuVernois
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, WI, USA
| | - R W Ellsworth
- School of Physics, Astronomy, and Computational Sciences, George Mason University, Fairfax, VA, USA
| | - K Engel
- Department of Physics, University of Maryland, College Park, MD, USA
| | - C Espinoza
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - K Fang
- Department of Astronomy, University of Maryland, College Park, MD, USA.,Joint Space-Science Institute, University of Maryland, College Park, MD, USA
| | - H Fleischhack
- Department of Physics, Michigan Technological University, Houghton, MI, USA
| | - N Fraija
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A Galván-Gámez
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - J A García-González
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - F Garfias
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A González-Muñoz
- Departamento de Física, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Mexico
| | - M M González
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - J A Goodman
- Department of Physics, University of Maryland, College Park, MD, USA
| | - Z Hampel-Arias
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, WI, USA.,Inter-university Institute for High Energies, Université Libre de Bruxelles, Brussels, Belgium
| | - J P Harding
- Physics and Theoretical Divisions, Los Alamos National Laboratory, Los Alamos, NM, USA
| | - S Hernandez
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - J Hinton
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - B Hona
- Department of Physics, Michigan Technological University, Houghton, MI, USA
| | | | - C M Hui
- NASA Marshall Space Flight Center, Astrophysics Office, Huntsville, AL, USA
| | - P Hüntemeyer
- Department of Physics, Michigan Technological University, Houghton, MI, USA
| | - A Iriarte
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A Jardin-Blicq
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - V Joshi
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - S Kaufmann
- Universidad Autónoma de Chiapas, Tuxtla Gutiérrez, Mexico
| | - P Kar
- Department of Physics and Astronomy, University of Utah, Salt Lake City, UT, USA
| | - G J Kunde
- Physics and Theoretical Divisions, Los Alamos National Laboratory, Los Alamos, NM, USA
| | - R J Lauer
- Department of Physics and Astronomy, University of New Mexico, Albuquerque, NM, USA
| | - W H Lee
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - H León Vargas
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - H Li
- Physics and Theoretical Divisions, Los Alamos National Laboratory, Los Alamos, NM, USA
| | - J T Linnemann
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI, USA
| | - A L Longinotti
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - G Luis-Raya
- Universidad Politecnica de Pachuca, Pachuca, Mexico
| | | | - K Malone
- Department of Physics, Pennsylvania State University, University Park, PA, USA
| | - S S Marinelli
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI, USA
| | - O Martinez
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | | | - J Martínez-Castro
- Centro de Investigación en Computación, Instituto Politécnico Nacional, Mexico City, Mexico
| | - J A Matthews
- Department of Physics and Astronomy, University of New Mexico, Albuquerque, NM, USA
| | | | - E Moreno
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - M Mostafá
- Department of Physics, Pennsylvania State University, University Park, PA, USA
| | - A Nayerhoda
- Institute of Nuclear Physics Polish Academy of Sciences, IFJ-PAN, Krakow, Poland
| | - L Nellen
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de Mexico, Mexico City, Mexico
| | - M Newbold
- Department of Physics and Astronomy, University of Utah, Salt Lake City, UT, USA
| | - M U Nisa
- Department of Physics and Astronomy, University of Rochester, Rochester, NY, USA
| | | | - J Pretz
- Department of Physics, Pennsylvania State University, University Park, PA, USA
| | | | - Z Ren
- Department of Physics and Astronomy, University of New Mexico, Albuquerque, NM, USA
| | - C D Rho
- Department of Physics and Astronomy, University of Rochester, Rochester, NY, USA.
| | - C Rivière
- Department of Physics, University of Maryland, College Park, MD, USA
| | - D Rosa-González
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - M Rosenberg
- Department of Physics, Pennsylvania State University, University Park, PA, USA
| | - E Ruiz-Velasco
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - F Salesa Greus
- Institute of Nuclear Physics Polish Academy of Sciences, IFJ-PAN, Krakow, Poland
| | - A Sandoval
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - M Schneider
- Santa Cruz Institute for Particle Physics, University of California, Santa Cruz, Santa Cruz, CA, USA
| | - H Schoorlemmer
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - M Seglar Arroyo
- Department of Physics, Pennsylvania State University, University Park, PA, USA
| | - G Sinnis
- Physics and Theoretical Divisions, Los Alamos National Laboratory, Los Alamos, NM, USA
| | - A J Smith
- Department of Physics, University of Maryland, College Park, MD, USA
| | - R W Springer
- Department of Physics and Astronomy, University of Utah, Salt Lake City, UT, USA
| | - P Surajbali
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - I Taboada
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, GA, USA
| | - O Tibolla
- Universidad Autónoma de Chiapas, Tuxtla Gutiérrez, Mexico
| | - K Tollefson
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI, USA
| | - I Torres
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - G Vianello
- Department of Physics, Stanford University, Stanford, CA, USA
| | - L Villaseñor
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - T Weisgarber
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, WI, USA
| | - F Werner
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - S Westerhoff
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, WI, USA
| | - J Wood
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, WI, USA
| | - T Yapici
- Department of Physics and Astronomy, University of Rochester, Rochester, NY, USA
| | - G Yodh
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA, USA
| | - A Zepeda
- Universidad Autónoma de Chiapas, Tuxtla Gutiérrez, Mexico.,Physics Department, Centro de Investigación y de Estudios Avanzados del IPN, Mexico City, Mexico
| | - H Zhang
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN, USA
| | - H Zhou
- Physics and Theoretical Divisions, Los Alamos National Laboratory, Los Alamos, NM, USA.
| |
Collapse
|
46
|
Barbarroja-Escudero J, Sánchez-González MJ, Pineda F, Rodríguez-Rodríguez M, Antolín-Amérigo D, Castillo M, Alvarez-Mon M. Identification of Lipoproteins From Sunflower Seeds in 2 Monosensitized Anaphylaxis Patients. J Investig Allergol Clin Immunol 2018; 28:334-336. [DOI: 10.18176/jiaci.0275] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Zamora C, Hung SC, Tomingas C, Atkinson C, Castillo M. Engorgement of Deep Medullary Veins in Neurosarcoidosis: A Common-Yet-Underrecognized Cerebrovascular Finding on SWI. AJNR Am J Neuroradiol 2018; 39:2045-2050. [PMID: 30237298 DOI: 10.3174/ajnr.a5783] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Accepted: 06/18/2018] [Indexed: 12/25/2022]
Abstract
We describe the prevalence and potential significance of deep medullary vein engorgement on SWI in patients with neurosarcoidosis, a finding that has not been described previously. Engorgement was evaluated for possible associations with meningeal or perivascular disease, intracranial hemorrhage, and venous thrombosis, as well as with modified Rankin Scale scores at the time of MR imaging and at follow-up. Deep medullary vein engorgement was seen in 7 of 21 patients and was more common in men. Patients with venous engorgement had a significantly increased incidence of microhemorrhages, perivascular disease, and hydrocephalus. There was no association with the degree of leptomeningeal disease, venous dural sinus thrombosis, or modified Rankin Scale scores. In conclusion, deep medullary vein engorgement was common in our patients with neurosarcoidosis. Although its pathophysiology remains uncertain, it could be related to venous or perivenous abnormalities and may represent a useful secondary finding of cerebrovascular disease.
Collapse
Affiliation(s)
- C Zamora
- From the Division of Neuroradiology, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
| | - S-C Hung
- From the Division of Neuroradiology, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - C Tomingas
- From the Division of Neuroradiology, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - C Atkinson
- From the Division of Neuroradiology, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - M Castillo
- From the Division of Neuroradiology, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| |
Collapse
|
48
|
Puac P, Rodríguez A, Lin HC, Onofrj V, Lin FC, Hung SC, Zamora C, Castillo M. Cavitary Plaques in Otospongiosis: CT Findings and Clinical Implications. AJNR Am J Neuroradiol 2018; 39:1135-1139. [PMID: 29622557 DOI: 10.3174/ajnr.a5613] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2017] [Accepted: 02/03/2018] [Indexed: 12/17/2022]
Abstract
BACKGROUND AND PURPOSE Cavitary plaques have been reported as a manifestation of otospongiosis. They have been related to third window manifestations, complications during cochlear implantation, and sensorineural hearing loss. However, their etiology and clinical implications are not entirely understood. Our purpose was to determine the prevalence, imaging findings, and clinical implications of cavitary plaques in otospongiosis. MATERIALS AND METHODS We identified patients with otospongiosis at a tertiary care academic medical center from January 2012 to April 2017. Cross-sectional CT images and clinical records of 47 patients (89 temporal bones) were evaluated for the presence, location, and imaging features of cavitary and noncavitary otospongiotic plaques, as well as clinical symptoms and complications in those who underwent cochlear implantation. RESULTS Noncavitary otospongiotic plaques were present in 86 (97%) temporal bones and cavitary plaques in 30 (35%). Cavitary plaques predominated with increasing age (mean age, 59 years; P = .058), mostly involving the anteroinferior wall of the internal auditory canal (P = .003), and their presence was not associated with a higher grade of otospongiosis by imaging (P = .664) or with a specific type of hearing loss (P = .365). No patients with cavitary plaques had third window manifestations, and those with a history of cochlear implantation (n = 6) did not have complications during the procedure. CONCLUSIONS Cavitary plaques occurred in one-third of patients with otospongiosis. Typically, they occurred in the anteroinferior wall of the internal auditory canal. There was no correlation with the degree of otospongiosis, type of hearing loss, or surgical complications. Cavitary plaques tended to present in older patients.
Collapse
Affiliation(s)
- P Puac
- From the Division of Neuroradiology (P.P., A.R., V.O., S.-C.H., C.Z., M.C.), Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - A Rodríguez
- From the Division of Neuroradiology (P.P., A.R., V.O., S.-C.H., C.Z., M.C.), Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - H-C Lin
- Radiology Department (H.-C.L.), Cathay General Hospital, Taipei, Taiwan
| | - V Onofrj
- From the Division of Neuroradiology (P.P., A.R., V.O., S.-C.H., C.Z., M.C.), Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - F-C Lin
- Department of Biostatistics and North Carolina Translational and Clinical Sciences Institute (F.-C.L.), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - S-C Hung
- From the Division of Neuroradiology (P.P., A.R., V.O., S.-C.H., C.Z., M.C.), Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - C Zamora
- From the Division of Neuroradiology (P.P., A.R., V.O., S.-C.H., C.Z., M.C.), Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - M Castillo
- From the Division of Neuroradiology (P.P., A.R., V.O., S.-C.H., C.Z., M.C.), Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| |
Collapse
|
49
|
Abeysekara A, Albert A, Alfaro R, Alvarez C, Álvarez J, Arceo R, Arteaga-Velázquez J, Avila Rojas D, Ayala Solares H, Belmont-Moreno E, BenZvi S, Braun J, Brisbois C, Caballero-Mora K, Capistrán T, Carramiñana A, Casanova S, Castillo M, Cotti U, Cotzomi J, Coutiño de León S, De León C, De la Fuente E, Diaz Hernandez R, Dichiara S, Dingus B, DuVernois M, Ellsworth R, Engel K, Enríquez-Rivera O, Fleischhack H, Fraija N, Galván-Gámez A, García-González J, González Muñoz A, González M, Hampel-Arias Z, Harding J, Hernandez S, Hona B, Hueyotl-Zahuantitla F, Hui C, Hüntemeyer P, Iriarte A, Jardin-Blicq A, Joshi V, Kaufmann S, Lara A, Lee W, León Vargas H, Linnemann J, Longinotti A, Luis-Raya G, Luna-García R, López-Coto R, Malone K, Marinelli S, Martinez O, Martinez-Castellanos I, Martínez-Castro J, Martínez-Huerta H, Matthews J, Miranda-Romagnoli P, Moreno E, Mostafá M, Nellen L, Newbold M, Nisa M, Noriega-Papaqui R, Pelayo R, Pretz J, Pérez-Pérez E, Ren Z, Rho C, Rivière C, Rosa-González D, Rosenberg M, Ruiz-Velasco E, Salesa Greus F, Sandoval A, Schneider M, Schoorlemmer H, Seglar Arroyo M, Sinnis G, Smith A, Springer R, Surajbali P, Taboada I, Tibolla O, Torres I, Villaseñor L, Weisgarber T, Westerhoff S, Wood J, Yapici T, Yodh G, Zepeda A, Zhou H. Constraining the
p¯/p
ratio in TeV cosmic rays with observations of the Moon shadow by HAWC. Int J Clin Exp Med 2018. [DOI: 10.1103/physrevd.97.102005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
50
|
Arango O, Trujillo A, Castillo M. Modelling gelation and cutting times using light backscatter parameters at different levels of inulin, protein and calcium. Lebensm Wiss Technol 2018. [DOI: 10.1016/j.lwt.2018.01.081] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|